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ABSTRACT
Engineering Cell-Free Biosystems for On-Site Production and Rapid Design of
Next-Generation Therapeutics
Kristen Michelle Wilding
Department of Chemical Engineering, BYU
Doctor of Philosophy
While protein therapeutics are indispensable in the treatment of a variety of diseases,
including cancer, rheumatoid arthritis, and diabetes, key limitations including short half-lives, high
immunogenicity, protein instability, and centralized production complicate long-term use and ondemand production. Site-specific polymer conjugation provides a method for mitigating these
challenges while minimizing negative impacts on protein activity. However, the locationdependent effects of polymer conjugation are not well understood. Cell-free protein synthesis
provides direct access to the synthesis environment and rapid synthesis times, enabling rapid
evaluation of multiple conjugation sites on a target protein. Here, work is presented towards
developing cell-free protein synthesis as a platform for both design and on-demand production of
next generation polymer-protein therapeutics, including (1) eliminating endotoxin contamination
in cell-free reagents for simplified therapeutic preparation, (2) improving shelf-stability of cellfree reagents via lyophilization for on-demand production, (3) coupling coarse-grain simulation
with high-throughput cell-free protein synthesis to enable rapid identification of optimal polymer
conjugation sites, and (4) optimizing cell-free protein synthesis for production of therapeutic
proteins.

Keywords: synthetic biology, cell-free protein synthesis, endotoxin removal, lyophilization,
lyoprotectant, unnatural amino acid, high-throughput screening
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INTRODUCTION

In the 1980’s, medicine was changed forever with the FDA approval of the first
recombinant therapeutic – human insulin – followed closely by a second, human growth hormone
[1]. Approval of these therapeutics marked the first approval of human proteins produced in E.
coli and ushered in a new age of medicine with the burgeoning field of synthetic biology [1]. The
ability to produce proteins in hosts other than their native organisms has enabled safe, large-scale
production of a wide variety of therapeutics such that the list of FDA-approved protein and peptide
therapeutics now reaches upwards of 240 [1]. These protein therapeutics have emerged as
indispensable components in the treatment of many diseases, including diabetes, arthritis, and
cancer, and comprised 7 of the top 10 best-selling drugs in 2017 [2]. However, development and
use of these protein drugs is accompanied by several key challenges: (1) many proteins are rapidly
filtered from the body in the kidneys, resulting in short half-lives which require frequent dosing
[3,4]; (2) protein therapeutics, particularly those not human in origin, often elicit immune
responses, which can further decrease drug activity and potentially result in dangerous
hypersensitivity reactions [4-6]; (3) proteins are highly susceptible to protease degradation,
thermal stress, and aggregation, which can further limit half-lives and increase immunogenicity
and requires stringent cold-chain storage [4-9]; and (4) stringent cold-chain storage requirements
for both proteins and the cellular machinery used to produce them limits the accessibility to these
vital therapeutics [8,9].
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Cell-free protein synthesis (CFPS) offers a promising platform for addressing these
challenges. CFPS presents multiple advantages over in vivo approaches for protein optimization
and on-demand production. Central advantages include rapid synthesis and high volumetric yields
[10-13], emancipation from cellular viability constraints to allow flexible reaction conditions [1216], direct access to the reaction environment due to the absence of a cell wall [12,13,16], and
broad scalability [17,18]. These attributes make CFPS a promising tool for addressing the
challenges associated with protein therapeutics. First, the open protein synthesis environment of
CFPS allows for simplified protein purifications for on-site production by eliminating the need for
sophisticated cell lysis equipment and enabling treatment of CFPS prior to protein expression to
reduce contamination [12,19]. The flexible environment independent of live cells and the directly
scalable nature of CFPS reactions also makes CFPS amenable to on-demand protein synthesis by
enabling lyophilization for shelf-stability and ease of transport [19]. Finally, because of the rapid
protein synthesis capability, flexibility, and scalability, CFPS lends itself well to the optimization
of engineered proteins for enhanced therapeutic development [20,21]. Here, we capitalized upon
these unique attributes of CFPS to both improve and apply CFPS technology towards the
improvement of protein therapeutics.

1.1

Project scope
The challenges inherent to protein therapeutics are complex and multi-faceted. The aim of

this project is to provide a tool to enhance access to and development of protein therapeutics.
Specifically, the objectives of this project are:
1. To eliminate endotoxin in CFPS systems to enable simplified purifications for ondemand protein production
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2. To enhance shelf-stability of CFPS systems to improve stability during transport and
storage towards distributed, on-site therapeutic production
3. To improve design of active, stable polymer-protein conjugates for next-generation
therapeutic development
4. To produce therapeutic proteins at high yields

1.1.1

Endotoxin elimination
Approximately one third of protein therapeutics are produced in E. coli, targeting a wide

variety of diseases. However, due to immune recognition of endotoxin (a lipid component in the
E. coli cell membrane), these protein products must be extensively purified before application to
avoid adverse reactions such as septic shock. Cell-free systems offer the unique ability to remove
endotoxin prior to protein synthesis. Here we evaluate three strategies for removing endotoxins
from E. coli cell lysate: Triton X-114 two-phase extraction, polylysine affinity chromatography,
and extract preparation from genetically engineered, endotoxin-free ClearColi® cells. We
demonstrate the first adaptation of ClearColi® cells to prepare cell-free extract with high protein
synthesis capability. Pre-expression endotoxin removal from CFPS reagents could simplify
downstream processing, potentially enabling on-demand production of unique protein
therapeutics.

1.1.2

Cryoprotected CFPS for improved shelf-stability
In recent years, lyophilized cell-free systems have widened the application space by

enabling improved stability outside of cold-chain storage. Current embodiments of the system,
however, demonstrate poor stability at elevated temperatures. Lyoprotectants have long been
recognized for the ability to preserve the activity of biological molecules during drying processes,
3

however the application of this technology to lyophilized cell-free systems has been limited. Here,
we demonstrate improved cryoprotection for stable, highly active lyophilized cell-free protein
synthesis capable of producing up to 10x protein yields of similar systems.

1.1.3

Site-specific PEGylated protein screening
PEGylation, or covalent attachment of polyethylene glycol (PEG) to proteins, is a well-

established method for addressing many of these issues. However, the traditional approach to
PEGylation generally involves targeting naturally reactive protein residues, such as lysines or the
N- or C-terminus, resulting in insufficient control over conjugation site and often significantly
reducing specific activity [3,22,23]. Unnatural amino acids (uAA) can be incorporated to provide
a unique handle for PEGylation [20,24], but optimal site selection for uAA-incorporation and sitespecific PEGylation is poorly understood. We apply CFPS towards evaluation of the locational
effects of uAA-incorporation and site-specific PEGylation and develop a computationallyefficient coarse-grain simulation model as a potential tool to enhance PEGylation site screening.

1.1.4

Optimized CFPS production of cancer therapeutic
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer. Successful

treatment using FDA-approved asparaginase therapies are plagued by extreme hypersensitivity
and rapid drug clearance. Additional reports of anti-PEG antibodies threaten the utility of currently
available PEGylated therapies for the disease, including pegaspargase. We demonstrate optimized
production of a second-line therapeutic for ALL, crisantaspase. This work demonstrates the first
reported production of highly active crisantaspase in a cell-free system. We further propose a
method for high-throughput optimization of site specific polymer conjugates of these therapeutics
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using a PEG-alternative, poly(2-ethyl-2-oxazoline). This technology could improve the
development of stabilized protein therapeutics.

1.2

Outline
This work focuses on developing CFPS technology towards addressing four key challenges

of protein therapeutics: (1) short half-lives, (2) immunogenicity, (3) limited stability, and (4) poor
accessibility due to stringent cold-chain storage requirements. The bulk of this dissertation
constitutes adaptations of publications (published or in-progress) which I have lead, developed,
and authored. In addition, this work frequently references, but does not include, several additional
publications which I either authored or coauthored (as summarized in Table 1-1).
Table 1-1: Work Summary & Outline

.
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2

ENDOTOXIN-FREE E. COLI-BASED CELL-FREE PROTEIN SYNTHESIS FOR
ON-DEMAND CANCER THERAPEUTIC PRODUCTION

Chapters 2 and Appendix A are adapted from a publication entitled “Endotoxin-free E.
coli-based cell-free protein synthesis: Pre-expression endotoxin removal approaches for ondemand cancer therapeutic production” (Wilding et al. 2018). The presented work was led and
conducted by myself, with contributions from my graduate student colleague Porter Hunt and
undergraduate students Joshua Wilkerson, Parker Funk, Rebecca Swensen, William Carver, and
M. Lance Christian, who I trained and supervised.

2.1

Introduction
The past few decades have seen a dramatic increase in the number of recombinant protein

therapeutics developed to target a wide variety of diseases such as cancer, arthritis, and diabetes.
Approximately one third of all these products are produced in E. coli [25,26]. The E. coli platform
is attractive for therapeutic production due to its low cost and rapid growth kinetics. However, like
other gram negative bacteria, E. coli produce high levels of lipopolysaccharide (LPS), or endotoxin,
during cell growth, division, and lysis. Human exposure to endotoxin activates an immune
response and can result in septic shock [25,27,28]. Therefore, therapeutics produced in E. coli must
be extensively purified to remove endotoxin to extremely low levels before administration [29].
This additional processing and quality control adds to the cost of protein therapeutic production,
with downstream processing in general accounting for 45-92% of total manufacturing costs [30].
6

The removal process can result in poor protein recovery, reduced protein activity, and the
introduction of contaminants which often necessitates optimization for each individual product
[25,27,30,31].
One potential solution is to use cell-free protein synthesis (CFPS), where the biological
machinery necessary for transcription and translation is harvested from cells and activated in vitro.
This approach to protein synthesis provides the unique potential to shift several processing steps
upstream, such as cell lysis and separation. Thus, the system provides an opportunity for endotoxin
removal prior to protein synthesis. This pre-expression endotoxin removal could potentially
simplify or eliminate downstream endotoxin removal steps. Pre-expression endotoxin removal
would be especially important for the emerging application of lyophilized CFPS technology for
on-demand, deployable therapeutic synthesis, which could enable rapid production of personalized
therapeutics or therapeutics in response to a pandemic threat [19,32-34]. Here, we evaluate three
methods of pre-expression endotoxin removal from CFPS systems. We report that conventional
methods of endotoxin removal from clarified E. coli cell lysate, or cell-free extract, show promise,
but significant cost and engineering is necessary to make these methods viable. By contrast,
optimized production of cell-extract from ClearColi® (an LPS-free genetically engineered BL21
DE3 E. coli strain) produced consistently high yields of protein without the need for specific
endotoxin removal steps. Further, we demonstrate production of a clinically relevant FDAapproved cancer therapeutic, crisantaspase, from low endotoxin and endotoxin-free E. coli cellfree extract.
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2.2

Materials and methods
Unless otherwise specified, materials were obtained from Sigma Aldrich (St. Louis, MO).

All falcon tubes, microcentrifuge tubes, and pipette tips were endotoxin-free. Additional details
are provided in Appendix A.

2.2.1

Extract preparation
Cell extracts were made using either E. coli BL21 StarTM (DE3) (Invitrogen, Carlsbad, CA)

or ClearColi® BL21 DE3 (Lucigen, Middleton, WI). Extract was produced as described
previously with either LB, 2xYT, or TB fermentation media [19,35-37].

2.2.2

CFPS pre-treatment
For pre-treatment studies, standard BL21 extract was treated using either Triton X-114

two-phase extraction or polylysine affinity chromatography. Triton X-114 extractions were
performed using 1% volume Trion X-114 according to a modification of a method previously
described for purified proteins [29,38,39]. Endotoxin content and protein production capacity of
extract samples were assessed after 1-3 cycles. For polylysine affinity chromatography treatment,
PierceTM High Capacity Endotoxin Removal Spin Columns, 0.5 mL were obtained from
ThermoFisher Scientific. Columns were equilibrated and washed as directed by the manufacturer.
1 mL samples of E. coli BL21 StarTM (DE3) extracts (referred to as BL21 (DE3*)) were diluted to
2 mL using endotoxin-free LAL reagent water (Lucigen, Middleton, WI), and applied to spin
columns as directed by the manufacturer.
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2.2.3

CFPS production of sfGFP and crisantaspase
CFPS of sfGFP was performed and yields assessed as previously described [19,40]. The

crisantaspase gene with a C-terminal linker (GGSGGS) and 6-His tag was purchased and cloned
into the pY71 vector (GenScript). Crisantaspase CFPS reactions were performed similarly to
previously described CFPS reactions, varying the yield using 12-36 nM DNA and incubating at
30°C for 8 hours or 37°C for 3 hours [20]. Reactions were performed in 20 µL – 400 µL volumes
in 2 mL microcentrifuge tubes (Bioexpress, Kaysville, UT) or 15 mL falcon tubes. Crisantaspase
was purified using Ni-NTA spin columns according to the manufacturer’s instructions. Soluble
protein concentration and the protein concentration of purified samples was determined via TCA
precipitation and scintillation counting as reported previously [20].

2.2.4

LAL testing
The endotoxin equivalent activity of the extracts, treated extracts, and purified samples was

determined using the LAL Kinetic Turbidimetric Assay (Lonza, Allendale, NJ) according to the
manufacturer’s instructions.

2.2.5

Crisantaspase activity assay
The activity of crisantaspase was assessed using an Asparaginase Activity Assay Kit

(Sigma Aldrich). Sample activity was determined by measuring the change in OD570 37°C using a
Synergy-MX microplate reader (BioTek, Winooski, VT).
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2.3

Results and discussion
The open format of CFPS provides the opportunity to remove or eliminate endotoxin prior

to protein expression, potentially reducing or eliminating downstream endotoxin removal steps to
enable on-demand, deployable therapeutic synthesis. However, to our knowledge, no attempt has
been made to remove endotoxin from E. coli extract prior to CFPS. Towards this end, we assessed
the impact of endotoxin removal before CFPS expression by the following approaches: Triton X114 phase extraction, polylysine affinity chromatography, and extract production from geneticallyengineered endotoxin-free ClearColi® E. coli cells (Figure 2-1).

Figure 2-1: Pre-expression Endotoxin Removal from CFPS Systems Simplifies On-site Processing. (Left)
Flowchart comparing workflow for the production and purification of protein therapeutics via in vivo E.
coli expression, Triton X-114 or polylysine affinity pre-treated E. coli-based CFPS, in vivo ClearColi®,
and ClearColi® CFPS. Dotted box represents a step which may or may not be necessary. Shading indicates
steps which could be performed on-site. (Right) Schematic of endotoxin-free extract production for ondemand therapeutic synthesis.

2.3.1

Pre-expression endotoxin removal from standard BL21 (DE3*)
Among the most common methods of endotoxin removal from purified proteins are Triton-

X-114 two-phase extraction and affinity chromatography [28]. While these methods have been
quite successful for some purified proteins, multiple protocol repetitions and trade-offs between
protein stability and removal efficiency can complicate treatments, reducing yields and protein
activities and introducing additional contaminants [27,30,31,38,41]. We therefore assessed the
10

potential of Triton X-114 extraction and polylysine affinity chromatography as endotoxin removal
methods for extract pre-treatment, testing the endotoxin content and protein synthesis capacity of
extracts after one or more cycles of one of the protocols.
As shown in Figure 2-2, both treatment methods significantly, but insufficiently, reduced
the endotoxin content of the treated extracts. Both methods also significantly reduced the protein
synthesis capacity. Of the two, Triton X-114 extraction was the most effective approach, removing
95% endotoxin after 3 treatments while maintaining ~30% protein synthesis capacity. The losses
of protein synthesis capacity are not surprising, considering the complex mixture of proteins, small
molecules, and macromolecules involved in protein transcription and translation which could be
lost during the extract treatment. However, the initial endotoxin content of CFPS extract (~18
million endotoxin units (EU) per mL – Figure 2-2) is orders of magnitude greater than that of
protein sample that has undergone purification steps prior to endotoxin removal
[25,27,29,38,42,43]. Thus ~99.999% of endotoxin would need to be removed to reach FDA
approved levels of endotoxin administration (on the order of 100 EU per mL) to eliminate the risk
of endotoxin toxicity and eliminate the need for endotoxin removal steps from CFPS-produced
protein [25,27,29,38,42]. Further optimization of Triton X-114 extraction protocols may enable
increased removal efficiencies beyond 95% and may mitigate some of the loss of CFPS
components [41]. However, considering the 70% loss in CFPS activity and the significant
concentration of residual endotoxin (1 million EU per mL), the current embodiments of extract
treatment methods are currently ill-suited towards large-scale applications.
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Figure 2-2: Pre-expression Extract Treatment Reduces Extract Endotoxin Content but Reduces Viability.
Endotoxin content, as measured by LAL reactivity (blue bars), and sfGFP production yields (white bars)
from untreated and treated standard E. coli extracts. x1, x3, x5, and x10 represents the number of extractions
or column passes. Error bars represent one standard deviation, where n ≥ 2 for LAL reactivity, n ≥ 3 for
sfGFP yield. When not visible, error bars are hidden beneath the markers.

2.3.2

Endotoxin-free ClearColi®-based extract
An alternative to pre-expression endotoxin removal for preparation of an endotoxin-free

CFPS system is to prepare extract from an E. coli strain that is inherently endotoxin-free. Recently
researchers have developed such a strain, the genetically modified BL21 DE3 E. coli strain
ClearColi® (ΔgutQ, ΔkdsD, ΔlpxM, ΔpagP, ΔlpxP, ΔeptA). In the ClearColi® membrane lipid, the
core oligosaccharide and two of the lipid chains from the LPS have been eliminated, rendering the
lipid unrecognizable to the toll-like receptor 4 (TLR4) complex responsible for the endotoxin
reaction in humans (Figure 2-3) [25,44,45]. This strain has therefore been shown in multiple
studies to be “endotoxin free” and can be used to produce therapeutics without downstream
endotoxin removal steps [25,26,45-47].
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Figure 2-3: E. coli lipid A (LPS) vs ClearColi® lipid IVA. Hexagons represent various sugars: grey = Dgalactose, orange = D-glucose, green = l-glycerol-D-manno-heptose, blue = 3-deoxy-D-manno-octulosonic acid. Yellow circle represents phosphate, light blue oval represents phosphoethanolamine.

Here we report the first use of ClearColi® to make cell-extract for CFPS and report its
viability in cell-free systems. The ClearColi® extract preparation procedure differs slightly from
that of standard extract due to the altered characteristics of the ClearColi® cells. ClearColi® cells
are reportedly more sensitive to osmolarity, grow at approximately half the rate of regular BL21
cells, and reach lower final densities [25,48,49]. Gene expression in bacteria changes dramatically
with growth rate and cell phase, making induction and harvest points important parameters when
preparing extract for CFPS [50,51]. Using the lab-scale shake-flask fermentation approach with
commonly used media, induction, and harvest protocols (detailed in 2.2.1 and 0), the protein
production yields from ClearColi® extracts were ~20% of regular BL21 DE3 extracts (Figure 2-4).
Therefore, in order to create a high-yielding ClearColi® extract, both the effect of media type on
the ClearColi® growth and the effect of induction and harvest times on cell-free extract activity
were investigated.
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Figure 2-4: Initial ClearColi Extract Yields. CFPS protein synthesis capacity of standard BL21 extract
compared to initial ClearColi® extract preparation, determined by sfGFP yields. The initial ClearColi®
extract was induced with 1 mM IPTG at an OD600 ~0.53 (~1.75 hours of growth after inoculation with 100
mL intermediate growth) and harvested when the growth rate was seen to decrease, indicating the start of
exit from log phase, at an OD600 of 1.47 (approximately 5.2 hours after inoculation with 100 mL
intermediate growth, ~3.4 hours after induction). Error bars indicate standard deviation from n ≥ 3.

2.3.3

Media optimization for ClearColi® extract preparation
Three different media formulations and varying levels of NaCl were tested: LB-Miller (the

recommended media for ClearColi® protein preparations), 2xYT media (reported to produce highyielding CFPS extracts), and TB media (which supports E. coli growth to higher cell densities)
[35,48,52]. The three media formulations were evaluated at increasing NaCl levels, as enhanced
ClearColi® growth has been suggested at higher osmolarity and ionic strength [52]. Thus, NaCl
was added to LB, 2xYT, and TB media ranging from original concentration in the media (10 gm/L
for LB-Miller, 5 gm/L for 2xYT, and 0 gm/L for TB) up to 20 gm/L. Results indicated that TB
media consistently facilitated faster final growth rates and higher cell densities, and that increasing
NaCl concentration beyond an additional 5 g/L did not significantly improve cell growth rates and
densities (Figure 2-5). Therefore, TB media with an additional 5 g/L or 10 g/L NaCl was used to
grow ClearColi® for cell-free extract preparation. While the ClearColi® growth rate with TB was
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faster than other media formulations, it remained lower than BL21 (DE3*) (~0.72±0.12 hr-1 vs
1.48±0.25 hr-1 characteristic growth rate as determined by the Verhulst-Pearl equation, Figure
2-6B). A comparison of the ClearColi® growth kinetics to BL21 (DE3*) is shown in Figure 2-6A.

Figure 2-5: ClearColi Media Optimization. (A)&(C): Growth curves and final instantaneous growth rates
from media optimization for 100 mL growths in 500 mL shake flasks, where orange curves are grown in
LB media, blue curves represent growths in 2xYT media, and green curves represent growths in TB media.
Note that TB media with 5 g/L or 10 g/L NaCl consistently reaches the highest OD600 during the growth
period, and TB with >0 g/L NaCl has highest final instantaneous growth rates (n=1-3); (B)&(D): Growth
curves and final instantaneous growth rates (average of n=2) from media optimization for 10 mL growths
in 50 mL falcon tubes, where orange curves are grown in LB media, blue curves represent growths in 2xYT
media, and green curves represent growths in TB media. Note that TB media again reaches the greatest
OD600 and is consistently among the highest final instantaneous growth rates. Oxygen transfer in the 50
mL falcon tubes may have been limiting, considering the lack of air flow through the cap, which may
explain some of the discrepancies in final OD600 and instantaneous growth rates between the 100 mL and
10 mL growths.
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Figure 2-6: ClearColi vs Standard BL21 (DE3*) Growth Parameters. (A) Growth curves for standard E.
coli BL21 (DE3*) in 2xYT media and ClearColi® in TB with 5 g/L and 10 g/L added NaCl. Smooth lines
represent Verhuslt-Pearl growth equation fits to the data; (B) Parameters obtained by regressing growth
data from Figure 2-6A to the Verhulst-Peart equation (right) for time-dependent, self-limiting population
growth, where P0 is the initial population, r is the growth rate, and k is the carrying capacity. Note that the
growth rate parameter, r, is significantly different between the BL21 DE3* strain and the ClearColi® strains,
but the growth rate of the ClearColi® is not significantly different between the two salt concentrations.

2.3.4

Early induction/harvesting produces high-yielding ClearColi® extracts
The induction and harvesting OD600 was next optimized for ClearColi® extract preparation.

IPTG induction is required for T7 RNA polymerase production and induction at 0.5 OD600 with
harvest at mid to late log phase has previously been shown to be optimal [35]. The impact of
induction and harvest OD600 on CFPS activity of ClearColi® extract was assessed (Figure 2-7A).
The highest yielding ClearColi® extracts were induced just before log phase (OD600 ~ 0.6) and
harvested in mid-log phase (OD600 2-3, ~5-7 g cell/L media). Interestingly, comparable CFPS
yields could be obtained when extracts were induced earlier (OD600 ~0.1) and harvested earlier
(OD600 0.6-2.5, ~2-5 g cells/L media). The sfGFP production yields of these highest performing
ClearColi® extracts were comparable to standard BL21 yields, at about 80-90% of the yields of
standard extract (Figure 2-7B).
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Figure 2-7: ClearColi Extract Induction/Harvest Optimization. (A) sfGFP yield from ClearColi® extracts
versus induction/harvest OD600; (B) Comparison of sfGFP yield from CFPS reactions using either BL21
(DE3*) extract versus induction/harvest optimized ClearColi® extract fermented with TB media, n ≥ 3,
error bars represent one standard deviation.

2.3.5

High titers of crisantaspase are produced using reduced-endotoxin CFPS
Crisantaspase (ErA) is an asparaginase derived from Erwinia chrysanthemi bacteria which

is FDA-approved as a secondary treatment for acute lymphocytic leukemia in patients who have
developed immune responses against the primary treatment, E. coli-derived asparaginase [53]. To
meet restrictions for intravenous administration, the administered endotoxin levels for ErA must
not exceed 5 EU/kg patient/hr [42]. Therefore, reducing the initial endotoxin contamination of the
sample could significantly simplify downstream purifications for this drug.
Active ErA was produced using the standard BL21 extract, Triton X-114-treated extract,
and ClearColi® extract, which is the first time to our knowledge that ErA has been produced using
CFPS. ErA yields for each of the three cell-free systems is shown in Figure 2-8A. ErA produced
in these reactions was purified via a single Ni-NTA affinity column, and the endotoxin content of
each sample was evaluated using the widely used limulus ameobocyte lysate (LAL) assay (Figure
2-8B). A single Ni-NTA spin column treatment reduced the LAL reactivity of ErA by greater than
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1000-fold for ErA produced using standard BL21 DE3 extract and Triton X-114-treated extract,
and by approximately 20,000-fold for ErA produced from the ClearColi® extracts (Table 2-1).
The ~10-fold higher reduction of LAL reactivity from the ClearColi™ CFPS-derived ErA
compared to the other extracts is consistent with previous reports that the absence of the
oligosaccharide in lipid IVA makes it easier to remove than standard LPS [25]. The residual LAL
activation from the ClearColi® derived product is likely due to the previously reported nonspecific nature of the LAL assay, which has been reported to react with a broader spectrum of
lipids than does the human immune system [25,46].The ErA produced in the Triton X-114-treated
extract had significantly reduced endotoxin concentration compared to the sample purified from
standard BL21 extract (Figure 2-8B), However, the lower yields of ErA with this system suggest
that, per mg protein, the current embodiment of the Triton X-114 treated extract may not produce
sufficiently reduced levels of endotoxin for intravenous administration after a single affinity
column purification. By contrast, ClearColi® extracts produced approximately ~70% as much ErA
as standard BL21 during short reaction times while Triton X-114 extracts produced ~25%.
Extended reaction times enabled comparable yields from both BL21 and ClearColi® extracts, at
up to 1 mg/mL ErA, and 0.45 mg/mL from Triton X-114-treated extract (Figure 2-8A). The higher
yield of the ClearColi®-derived extract, coupled with the simplicity of extract preparation and the
reported activity of the lipid IVA as an antagonist rather than an agonist for endotoxin response in
humans, makes the cell-free ClearColi® system a promising approach to simplify purification
requirements of deployable, on-demand therapeutic synthesis [45]. In addition, the ErA produced
in the new ClearColi® extract retained the same activity of that produced in BL21 (DE3*) extract
(Figure 2-8C).
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Figure 2-8: Cell-free Protein Synthesis of Active, Endotoxin-free Crisantaspase at High Yields. (A)
Endotoxin content determined by LAL kinetic turbidimetric assay of ErA samples purified by His-tag
purification with single pass Ni-NTA spin columns from CFPS reactions using BL21 (DE3*) extract,
ClearColi® extract, or Triton X-114-treated BL21 (DE3*) extract. The remaining endotoxin levels for the
ClearColi® sample are attributed to the non-specific nature of the LAL assay. Error bars represent standard
deviations, n=4; (B) Specific activity of ErA samples produced in cell-free using BL21 (DE3*) extract or
ClearColi® extract, normalized by protein concentration to 1 mg/mL ErA. Negative control is a buffer-only
control. Error bars represent standard deviations, n = 8. (C) Increasing reaction times improves ErA yields.
Increasing DNA concentrations were tested at both 37°C for 3 hours and 30°C for 8 hours. In most cases,
increasing DNA did not have a significant effect on BL21 (DE3*) or ClearColi® reactions at the shorter
time periods. Incremental improvements in the yield from Triton X-114 treated extract were observed at
higher DNA concentrations, though yields remained significantly lower than those from the other two
extract types. For BL21 (DE3*) and ClearColi®, an additional DNA condition was tested, where reactions
were initiated with 18 nM DNA, and then 18 nM more DNA was added after 45 min for 3 hour reactions
or 3 hours for 8 hour reactions. No significant improvement in yield was observed for these conditions. For
all three extract systems, greatest ErA yields were obtained during the 8 hour reactions. Error bars represent
the standard deviation for n ≥ 3.
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Table 2-1: LAL Reactivity of Purified Samples from CFPS Platforms.
LAL Activity of Ni+ purified
sample (EU/mL)
BL21(DE3)*
ClearColi
BL21(DE3)*, 3x Triton X-114

13849

± 1739

356
1214

± 171
± 502

Compared
to BL21

Fraction of Initial LAL Activity
Remaining

100.0% 3.34E-04 ±

4.20E-05

2.6% 4.91E-05 ±
8.8% 3.36E-04 ±

2.36E-05
1.39E-04

LAL Activity after one Ni+ affinity purification is significantly reduced for the samples produced
via ClearColi CFPS compared to the other two methods. Furthermore, Ni+ purification reduces
LAL Activity for the ClearColi sample by nearly 10-fold more than the other E. coli-based samples
due to the altered LPS structure. LipidIVA is detected by the LAL assay, but does not elicit an
immune response in humans [25].
2.3.6

Conclusions
The presence of endotoxin is a limitation of E. coli-based CFPS systems and holds the risk

of septic shock if not adequately removed during purification. Triton X-114 treatment significantly
reduced but did not eliminate endotoxin content and allowed up to 45% yields. By contrast, highly
active and inherently endotoxin-free extract was produced using the ClearColi® cell strain after
extract preparation procedures were modified to account for the altered growth kinetics of this
strain. In addition, consistent production of significant amounts of the clinically relevant
therapeutic protein crisantaspase (ErA) was demonstrated using this system. The presented
platform improves upon the endotoxin-free in vivo production enabled by the ClearColi® strain
by shifting steps such as fermentation and lysis upstream to enable rapid therapeutic synthesis in
a ready-to-use, open format which is more amenable to deployable, on-demand production. The
presented platforms are an important step towards on-site therapeutic production, potentially
allowing rapid synthesis of therapeutic proteins without the need for complex downstream
purifications.
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3

ANTIPLASTICIZED LYOPHILIZED CELL-FREE PROTEIN SYNTHESIS
SYSTEMS FOR ENHANCED STABILITY AND ON-DEMAND THERAPEUTIC
PRODUCTION

Having developed an endotoxin-free CFPS platform, the next aim of this work was to further
the potential of this platform to enable rapid, on-demand therapeutic synthesis by stabilizing CFPS
reagents for shipping, storage, and on-site protein production. Here, we build upon previous work
by our lab, in which standard extract systems were stabilized for room temperature storage via
lyophilization, by employing various lyoprotectants to enhance the stability of stored extracts and
to develop a stabilized, “just-add-water” system for protein synthesis. The following work is being
prepared for dissemination in a peer reviewed journal. The presented work was primarily led and
conducted by myself, with contributions from my graduate student colleague Emily Long Zhao
and undergraduate students Conner Earl and Rebecca Swensen who I trained and supervised.

3.1

Introduction
Protein therapeutics have emerged as some of the most promising treatments to a wide

variety of diseases, including diabetes, arthritis, and cancer [12,16,33,54]. As biotechnology and
understanding of disease mechanisms continue to improve, personalized protein therapeutics may
become increasingly possible and impactful [8,54]. However, several aspects of the current
paradigm for production and distribution preclude the on-site, on-demand synthesis essential for
personalized medicine on emergency response. First, biologic production is primarily done in live
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cells, necessitating specialized facilities, trained experts, and stringent quality control, which
generally restricts the production to centralized facilities [8,9]. Second, limited stabilities of
proteins often necessitate cold-chain storage during transportation and storage, which can limit
access in remote areas without the proper distribution framework [8].
Cell-free protein synthesis has emerged as a method to circumvent many of the limitations
associated with dependence on live cells for protein expression. Cell-free systems provide direct
access, facile scalability, and emancipation from cell viability constraints, which can better enable
small-scale or potentially automatic therapeutic production and simplified purification [12,13,34].
When coupled with the ability to produce protein directly from linear PCR products, these
attributes lend the CFPS system towards rapid on-demand protein production [40,55]. However,
cell-free reagents traditionally require the same cold-chain storage as other biological reagents,
limiting the potential for distributed, point-of-use synthesis.
For traditional purified proteins, the cold-chain storage and stability issues are often
mitigated by storing and distributing the samples in a lyophilized state. However, this strategy
precludes on-demand synthesis of small batches of therapeutics, such as would be necessary for
personalized therapeutics and stratified medicine [8]. Additionally, protein denaturing and
aggregation during the lyophilization and storage process can reduce the activity of the lyophilized
therapeutics and increase their immunogenicity [56,57]. An alternative would be to stabilize the
expression system for transit and storage, enabling on-site production of fresh protein as needed
(Figure 3-1). Accordingly, we recently demonstrated for the first time that lyophilization of cellfree protein synthesis reagents confers stabilizing benefits, enabling enhanced activity after
prolonged storage at room-temperatures while simultaneously rendering the reagents sterile [19].
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More recently, our lab and others have demonstrated the potential to lyophilize whole cellfree systems onto paper towards low-cost, on-demand biosensing and production of a variety of
therapeutics [9,58,59]. While these studies have demonstrated significant progress, they have been
limited to room-temperature studies, costly PURE (protein synthesis using recombinant elements)
CFPS reagents, extremely small-scale volumes, and have necessitated storage under an inert
nitrogen atmosphere and silica desiccant, and hence would be impractical for larger scale reactions
for on-demand and stratified medicine applications [59]. Furthermore, actual GFP yields were not
reported and therapeutic proteins were produced from extracts which were presumably not stored
after freeze-drying. Finally, a straightforward protocol for generation of the microscale lyophilized
products is not given. Other previously demonstrated lyophilized CFPS systems have similarly
lacked applicability to large-scale operations [60]. Therefore, we sought to create a simple, more
robust, scalable procedure for stabilizing extract and whole-cell free reactions at a variety of
temperatures relevant for transportation and storage of CFPS reagents for distributed, on-demand
therapeutic production.
In order to ensure activity of lyophilized CFPS reagents after transportation to and storage
at remote locations, CFPS reagents must be stabilized against degradation at elevated temperatures
such as those which may be encountered during unrefrigerated transport. Despite significant
improvement over aqueous systems, previously reported lyophilized systems retain minimal
viability after even short times at elevated temperatures [19,60]. A method commonly employed
to stabilize purified proteins involves addition of sugar molecules, most commonly disaccharides
such as trehalose, to the protein formulation prior to drying [57,61-65]. Addition of sugars as
lyoprotectants in lyophilized protein preparations is common-place [57,61-65]. However, this
stabilization has been only minimally explored towards the stabilization of whole cell-free protein
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synthesis systems and was plagued by marked inhibitory effects of the selected lyoprotectant,
trehalose [60]. While the exact mechanism of sugar-based stabilization for lyophilized protein
preparation is not completely elucidated, two primary mechanisms have been posited: (1) water
replacement or (2) vitrification [57,64,66,67]. In the first mechanisms, sugars are hypothesized to
gradually replace water in hydrogen bonding at the surface of proteins during the drying process
[57,64,66,67]. For this interaction-based stabilization, small sugars such as disaccharides are
thought to be most beneficial, as large polymeric sugars are thought to be more rigid and less
accessible to hydrogen bonding with the protein surface as compared to small disaccharides
[56,57]. Conversely, polymeric sugars are thought to stabilize protein matrices via the second
mechanism, vitrification. Relaxation dynamics in glasses take place over multiple time-scales,
from picoseconds to milliseconds [56]. The fast relaxation dynamics, referred to as the β
relaxations, are related to the vibration of molecules and diffusion and have been shown to be the
most related to protein stabilization [56,57]. Slowing these relaxations can stiffen the glass and
thereby stabilize the protein. In this way, addition of small amounts of small-molecules to a glass
with a higher Tg, termed antiplasticization, has been shown to increase the stability of lyophilized
protein/sugar-glass matrices by slowing the fast β relaxations, stiffening the material to slow
protein motion despite lowering the Tg [56,63,65,67-73]. Indeed, significant improvements to the
stability of lyophilized protein/sugar-glass formulations have resulted from addition of small
molecules and intermediate linker molecules to sugar-glasses, particularly for polymeric sugar
glasses [67,70]. However, despite the success of antiplasticization in lyophilized purified protein
preparations [56,63,65,68-72], the approach has not been investigated in the context of the much
more complex environment of lyophilized whole cell-free systems.
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We therefore sought to apply the principles of antiplasticization towards the stabilization of
lyophilized CFPS systems in order to enhance their stability for storage at elevated temperatures.
It has been previously reported that residual water can act as a plasticizer [64,66,74]. Given that
we were storing samples exposed to atmospheric conditions, such that some rehydration during
storage was a risk, we selected only lyprotectants with high Tg so as to ensure that the overall glass
would still have sufficiently high Tg in the presence of small amounts of residual water. Due to the
complex and incompletely understood interactions involved in antiplasization, optimal glassformer/linker/plasticizer combinations are difficult to predict [57,70]. Therefore, we selected two
antiplasticized polymeric glasses for our study – ficoll/maltitol/DMSO (FMD) and
dextran/maltitol/DMSO (DMD) – which have heretofore proved successful for the stabilization of
purified protein [70]. In addition, due to the reported success with trehalose as a cryprotectant [60],
we also included trehalose and trehalose plasticized by DMSO in our study. Our objectives for this
work are three-fold: (1) enhance the stability of CFPS systems to keep greater yield at elevated
temperatures, (2) create a CFPS system which retains viability after storage at extreme temperature
storage, and (3) create enhanced, truly “just-add-water” system amenable to distributed, ondemand therapeutic synthesis.
Here, we demonstrate enhanced preparation of CFPS systems for on-demand therapeutic
production by (1) enhance CFPS stability at elevated temperatures by identifying favorable
alternative lyoprotectants which enhance the stability of stored CFPS systems without negatively
effecting productivity, including multiple antiplasticized matrices, (2) providing a simple, more
industrially relevant protocol to produce lyophilized samples robust against standard atmospheric
conditions, and (3) demonstrating a simple, stable, and industrially relevant truly “just-add-water”
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cell-free protein synthesis system to enable facile transportation and storage of CFPS systems for
on-demand therapeutic production.

Figure 3-1: Lyophilized cell-free systems enable distributed, on-demand therapeutic protein synthesis.

3.2

3.2.1

Materials and methods

Extract preparation
Extracts were prepared from BL21 (DE3*) and ClearColi BL21 (DE3) strains as described

previously [12]. Briefly, cells were grown in 2.5 L tunair flasks (IBI Scientific, Peosta, IA) and
production of T7 RNA polymerase was induced via addition of 1 mM IPTG (GoldBio, St Louis,
MO) during early exponential growth (O.D.600 ~ 0.1 – 0.4). Cells were then harvested in mid log
phase (O.D.600 ~2-3) by centrifuging at 6,000 rpm for 10 minutes. Finally, cells were homogenized
at 21,000 psig via 3 passes in an Avestin French Press, and the lysate clarified by centrifugation
at >12,000 rcf.

3.2.2

Lyophilization
For samples with lyoprotectants added, protectants were added to a final weight percent of

20% of the final solution. For samples lyophilized with PANOxSP energy mix (made as previously
described [75]), a 1:1 by volume mixture was used. Two lyophilization methods were initially
investigated, using either a LabConco machine and drying multiple samples simultaneously inside
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the inner chamber or using a FlexiDry manifold freeze drying with each sample in an individual
peripheral tube. Results between the two drying methods were very similar (Figure B-1), so due
to the significantly faster drying time with the FlexiDry method, this setup was used for the
remainder of the experiments.
Control and cryoprotected samples were loaded into 75 mL cylindrical glass vials
(Labglass), and frozen in a -40°C ethanol bath (Just-A-Tilt Shell Freezer Chiller SF-4Az, FTS
Systems, Warminster, PA). Vials were then connected to the manifold of the freeze dryer (Flexidry MP, FTS Systems). System pressure remained ≤ 300 mTorr, with a collector temperature of 60°C. At 45 minute intervals, samples were removed briefly for weighing, and then promptly refrozen in the shell freezer and re-attached to the manifold. After approximately 1.5 hours samples
reached the minimum weight, corresponding to approximately 10% of initial extract weight.
Sample weight remained constant over an additional hour of freeze drying, suggesting that samples
were sufficiently dried. Remaining water content was estimated to be < 3% using Equations B-1
through B-3. Dried sample shells were then carefully ground with chemical spatulas, aliquoted by
mass into 1.5 mL microcentrifuge tubes for storage. Because the tubes were not vacuum-sealed or
back-filled with inert gas, samples were exposed to air during storage.

3.2.3

Rehydration ratio determination
Estimated rehydration ratios were calculated from the initial and dried sample weights

according to Equation 3-1, where RHRest is the estimated rehydration ratio and wtinitial and wtdried
are the initial and dried weights of the sample, respectively. A DCTM protein assay (Bio-Rad,
Hercules, CA) was performed on the rehydrated extracts per the manufacturer’s instructions to
verify that the extracts were rehydrated to the correct protein concentration compared to standard
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aqueous extract. Results and the estimated rehydration ratios are included in Figure B-3 and Table
B-1.
𝑅𝑅𝑅𝑅𝑅𝑅𝑒𝑒𝑒𝑒𝑒𝑒 =

3.2.4

𝑤𝑤𝑡𝑡𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 − 𝑤𝑤𝑡𝑡𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑

(3-1)

𝑤𝑤𝑡𝑡𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑

Cell-free protein synthesis
Yield of the stored extracts at each point was assessed by the production of sfGFP. These

reactions were performed as described previously in triplicate [12].

3.3

3.3.1

Results

Antiplasticization improves lyophilized extract storage stability at high temperatures
We first determined the impact of the various lyoprotectant systems on storage stability of

lyophilized E. coli cell-free extract with the goal to improve the viability of the system above that
previously reported [19,60]. E. coli extracts were prepared as previously reported [12].
Cryprotectants were then added to the extract to a final weight of 20% of the solution for all
samples except ficoll-based samples, in which additives totaled 11% by weight of the solution due
to solubility constraints. The 20% or 11% solution weight which accounted for lyoprotectants was
split between each additive as reported in Table 3-1, based on previously determined optimal ratios
[63,65-67,70]. Samples were lyophilized over a period of 2.5 hours, with less than 3% estimated
water remaining in all cases (see Equations B-1 through B-3). Dried extract pellets were then
ground and aliquoted into 1.5 mL eppindorf tubes for storage. Rehydration ratios were calculated
based on the water removed, and verified via DC assay analysis (Figure B-2, Figure B-3, and Table
B-1). At each time point, aliquots of dried extract stored at each temperature were rehydrated with
the appropriate amount of sterile ultrapure water by weight. Viability was then assessed by
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measuring sfGFP yields produced from each rehydrated sample (Figure 3-2A). sfGFP yields were
calculated as previously reported [12]. Results are depicted in Figure 3-2B - E.
Table 3-1: Protectant Fractions in Aqueous Extract Samples Before Lyophilization.

3.3.1.1 Extract storage at 4°C
The lowest temperature investigated in our study was 4°C. Because storage at 4°C requires
only a standard refrigerator, we reasoned that this storage temperature could reasonably be
obtained for long-term storage under many circumstances. At 4°C storage, all samples retained
activity very well. Over the course of 3 months, the control, DMD, and FMD systems maintained
approximately 90% of the activity of fresh extract. Trehalose-protected samples retained the least
activity, at approximately 25% of full extract activity throughout the duration of the test. The
sample protected with DMSO-plasticized trehalose initially exhibited low activity (~4%) but
appeared to recover slightly over the first few weeks, eventually performing similarly to the
trehalose-protected samples after 1-2 weeks. Over long-term storage at 4°C, trehalose/DMSO
protected samples performed similarly to trehalose-protected samples.
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Figure 3-2: CFPS Yields for Extracts Lyophilized with and without Protectants After Storage at 4°C, 25°C,
37°C, and 50°C.

3.3.1.2 Extract storage at 25°C
During storage at a warm room temperature of about 25°C during the experiment,
lyoprotectants were more beneficial than at 4°C. While control lyophilized extract maintained
approximately 25% activity after 3 months, which is in good agreement with our previously
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reported results [19], DMD- and FMD-protected samples each retained upwards of 36%. The
polymeric protectant samples also maintained greater than 90% activity over 1 week, which is
beneficial for unrefrigerated transport of these freeze-dried systems. As at 4°C, the trehalose- and
trehalose/DMSO- protected samples retained the lowest activity at 25°C, remaining at
approximately 20% of full activity throughout the duration of the 3-month test. Interestingly, the
trehalose/DMSO-protected samples appeared to have an initial recovery period, similar to that
seen at 4°C, however the recovery period appeared to be shorter than at 4°C.
3.3.1.3 Extract storage at 37°C
Storage at high temperatures such as 37°C is of interest for transport to remote locations
and storage at facilities with no air conditioning or refrigeration capacity. Control and DMD- or
FMD-protected samples retained over 50% activity after 1 week storage at 37°C. Control
lyophilized extract maintained approximately 19% of full activity after 3 months storage under
these conditions. After 3 months, trehalose-protected extract was approximately as active as the
control, at about 20% of full activity, having maintained approximately constant activity
throughout the 3 month period. Trehalose/DMSO-protected samples again performed very
similarly to trehalose-protected samples, reducing in activity after 3 months to about 12%. DMD
samples initially maintained slightly higher activity than the extract-only control, but after 3
months were approximately equivalent to the control at 20% full extract activity. Both DMD- and
FMD-protected samples maintained >50% activity for nearly 2 weeks. FMD-protected samples
performed the best of those tested at >30% full extract activity after 3 months, approximately a
40% improvement over the extract-only lyophilized control.
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3.3.1.4 Extract storage at 50°C
Storage at 50°C represents storage under extreme conditions, nearing the maximum
recorded temperatures on earth. Storage at high temperatures can also be useful in predicting longterm storage at lower temperatures. At 50°C, all samples reduced to less than 50% activity within
the first week. After 3 months, the control extract was no longer viable. Trehalose samples retained
about 13% of full extract activity after 3 months, again remaining approximately constant over the
entire test period. Trehlaose/DMSO-protected samples performed the poorest, completely losing
viability after the first week. DMD-protected samples initially performed the best, retained about
47% activity after the first week, however over the final two months the activity reduced to
approximately 3%, barely out-performing the control. FMD proved the most advantageous
protectant for extreme temperature storage, maintaining activity similar to the control during the
first month and approximately >15% full extract activity after 3 months storage at 50°C.

3.3.2

Lyophilized whole-CFPS system retains high activity at room temperature
We next investigated the potential for lyophilizing a complete CFPS system for “just-add-

water” on-demand protein synthesis. Our approach is unique compared to previous approaches, as
(1) both energy mix and extract are manufactured in-house, reducing costs compared to previously
reported commercial systems [35,59], (2) larger volumes and related methods are more amenable
to large-scale production and protein synthesis with minimal specialized equipment compared to
previously reported paper-based and micro-scale reactions [59], (3) stability is demonstrated under
harsher conditions involved in atmospheric storage where samples are exposed to oxygen and
water, and (4) our system demonstrates stability of the high-energy compound PEP, the basis of
some of the highest-yielding CFPS energy systems [19,76,77].
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Cell-free reactions were assembled as previously described [12], except that additional
water and DNA were excluded (Figure 3-3A). The mixed reactions were then lyophilized and
aliquoted into 1.5 mL microcentrifuge tubes for storage. Results are shown in Figure 3-3B. After
1 month storage at room temperature, the freeze-dried CFPS reactions (CFRxlyo) retained greater
than 60% of yields with fresh extract and fresh PANOxSP (~ 0.6 mg/mL). While the yield of the
stored CFRxlyo system is initially lower than that of lyophilized extract with fresh PANOxSP
(xSTDlyo + PANOxfresh), after approximately 2 weeks of storage CFRxlyo such that after 1 month
of storage CFRxlyo yields are approximately 2x higher. Although exact yields were not reported in
a previous study using trehalose-protected CFPS [60], based on normalized data provided and the
standard GFP yields reported the present yields are at least 10x higher.

Figure 3-3: Storage of Whole-CFPS (CFRxlyo) at 22°C Compared to Stored Lyophilized Extract with Fresh
PANOx [xSTDlyo + PANOxfresh. For reference the average sfGFP yield fresh extract and fresh PANOx
(CFRxfresh) is also shown as a dotted line.

3.4

Discussion
We have demonstrated the feasibility of applying the technology of antiplasticization to

enhance the preservation of lyophilized CFPS extract. After 12 hours of storage at 4°C, the control
extract lyophilized without lyoprotectants as well as the Dextran/Maltitol/DMSO (DMD) sample
and Ficoll/Maltitol/DMSO (FMD) sample had lost no activity over fresh extract samples,
33

indicating that the extract was robust against the lyophilization method and that these
lyoprotectants were not inhibitory of CFPS at the levels added. The negligible loss in activity
following lyophilization indicates that protein stability during the lyophilization process is not a
major concern for lyophilized extracts. Indeed, components native to the complex extract mixture
may already be filling the role of a lyoprotectant in stabilizing the protein components during
drying. This hypothesis is further supported by our previous work in which sucrose, another
disaccharide commonly used to stabilize proteins during drying, failed to improve the stability or
activity of lyophilized extract [19]. Therefore, we hypothesize that stabilization afforded to freezedried extract by sugar components can be attributed largely to the second proposed mechanism of
sugar-based cryoprotection: vitrification. None of the tested combinations of protectants proved
beneficial at 4°C; however, due to the high retained activity it is reasonable that no perceptible
benefit would be achieved with the lyoprotectants. It is also reasonable that antiplasticization had
no significant benefit at 4°C, as the β relaxations of the lyophilized extract glass at this temperature
may be sufficiently slow as to not benefit from increased stiffening of the matrix. At increased
temperatures, there was a notable benefit to cryoprotection with the plasticized polymeric glasses.
Both DMD and FMD plasticized glasses significantly stabilized lyophilized extract at room
temperature, producing nearly 1.5 times the sfGFP yield compared to control lyophilized extract
after 3-month storage at room temperature. Similarly, at 37°C and 50°C, the FMD-protected
samples outperformed the control extract after 3 months storage and at nearly every time point
tested. These results support the hypothesis that degradation of lyophilized extract is primarily due
to molecular vibrations, which are increased at higher temperatures. Therefore, plasticized
polymeric glasses would provide enhanced stability at temperatures sufficiently higher than the Tg
of the resulting glass.
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Trehalose has been used successfully in the past to stabilize multiple proteins and was
recently demonstrated to improve yield retention of lyophilized CFPS systems [60,65,66,68,7173]. Because of its small size and relatively high Tg, trehalose may potentially stabilize lyophilized
protein formulations by both the water replacement and vitrification mechanisms [60,65,66,68,7173]. However, due to the complex nature of CFPS systems, a trade-off exists between high initial
CFPS yields, which are reduced with increasing trehalose concentration, and high percent activity
retention [60]. At 20 wt%, a similar fraction previously reported to be stabilizing for CFPS,
trehalose appears to have a pronounced negative effect on the activity of CFPS. Indeed, over every
temperature and time point tested, the maximum sfGFP yield obtained with a trehalose-protected
system remained less than 30% of full extract activity. Therefore, although trehalose-protected
samples did consistently maintain nearly 100% of the initial sample activity for all temperatures,
higher even than the retention previously reported [60], the low initial yields of this system render
it inferior to other protection systems and even to control lyophilized extract at all conditions
except high temperatures for extended periods of time.

After extended storage at high

temperatures, trehalose-protected extract performs similarly to extract protected with
antiplasticized polymeric glass such as FMD. Therefore, in our study we have shown that ficoll
antiplasticized with maltitol and DMSO is preferable to trehalose as a lyoprotectant for CFPS
reagents.
The high yield of the CFRxlyo samples demonstrates the capacity of CFPS for distributed,
on-demand protein production for applications such as personalized medicine, point-of-care
therapeutic production, and emergency therapeutic generation such as for pandemic response. Our
CFRxlyo systems outperform similarly reported systems and offer an atmospherically robust, more
scalable approach than others previously reported [59,60]. The enhanced storage of the combined
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CFPS components is in contrast to previous reports which have reported higher yields when energy
mix is stored separately from CFPS extract [60], but is reasonable considering previous
demonstrations that multiple amino acids, all contained in the energy mix, can act as lyoprotectants
[78]. Indeed, we hypothesize that the potentially lyoprotectant activity of the energy mix on the
lyophilized extracts increasingly compensates for the loss in energy mix activity over time,
rendering the CFRxlyo system more active than xSTDlyo + PANOxfresh after extended storage at
elevated temperatures. This could explain why the CFRxlyo system initially has lower yields than
xSTDlyo with fresh extract, which could potentially be attributed to an initial pronounced decrease
in the activity of the energy system upon storage at elevated temperatures as seen with storage of
aqueous PANOx [19]. As the decline in energy mix activity slows, its lyoprotectant activity on the
freeze-dried extract may compensate for the decreased energy mix activity my preserving
significantly greater extract activity. Future work testing fresh PEP and other high-energy
components with a stored, lyophilized extract and amino acid mixture may further elucidate the
mechanism of CFRxlyo stabilization. Additional work may also further improve the stability of
such systems through thorough optimization of lyoprotectant combinations and ratios, and by
investigating the stability under an inert atmosphere.

3.5

Conclusions
We have demonstrated enhanced stability of lyophilized CFPS extracts through

antiplasticization. These antiplasticized lyophilized extracts are stable over a broad temperature
range, ensuring their stability against a variety of conditions potentially encountered during various
transportation methods and storage conditions. Furthermore, we have demonstrated the storage
stability of a one-pot “just-add-water” CFPS system under atmospheric storage conditions.
Coupled with our recent demonstration of high-yield endotoxin-free extract production, the
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production of a highly active, one-pot “just-add-water” CFPS system using straight forward inhouse reagent preparation procedures and minimal specialized equipment is an important step
towards industrially relevant production of protein expression systems for on-demand therapeutic
manufacture.
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4

THE LOCATIONAL IMPACT OF SITE-SPECIFIC PEGYLATION:
STREAMLINED SCREENING WITH CELL-FREE PROTEIN EXPRESSION AND
COARSE-GRAIN SIMULATION

PEGylation is an invaluable approach to stabilizing and mitigating the immunogenicity of
protein therapeutics, however, locational impacts of PEGylation are not well understood.
Therefore, for rapid development of enhanced therapeutics for on-demand applications such as
stratified medicine, a rapid screening approach is needed to identify optimal PEGylation sites.
Chapters 4 and Appendix C are adapted from the publication “The Locational Impact of SiteSpecific PEGylation: Streamlined Screening with Cell-free Protein Expression and Coarse-grain
Simulation” (Wilding et al. 2018) published in ACS Synthetic Biology in February 2018. The
presented work was designed, led, and conducted by myself, with contributions from my graduate
student colleagues Addison Smith and Derek Bush as well as undergraduate student Joshua
Wilkerson.

4.1

Introduction
Since its invention in the 1970’s, PEGylation has proved to be a valuable tool for

pharmaceutical applications [79-82]. Several PEGylated therapeutics are already available for
clinical use including the 15th best-selling pharameutical Neulasta [2,5,6,80]. PEGylated
therapeutics are reported to have improved pharmacokinetics and reduced immunogenicity, due to
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slower renal filtration and increased resistance to degradation and aggregation [83-87]. Enzyme
biocatalysts could similarly benefit from PEGylation through improved stability and greater
hydrodynamic radius, leading to improved recoverability and retention in matrices [5,88].
However, commercially available PEGylated proteins to date are non-specifically PEGylated,
targeting multiple natural residues such as lysine or cysteine [4,89], or are produced by targeting
naturally occurring, uniquely reactive sites, such as the N- or C- terminus [6,90], disulfide bonds
[91], or at less prevalent natural amino acids such as cysteine which have been mutated into the
protein [92,93]. Because these techniques limit the sites available for targeting, the tethering
locations on the protein may be in suboptimal locations such that conjugation would hinder protein
stability or important protein-protein interactions [90], both of which can dramatically reduce the
protein’s activity. In some proteins, application of these techniques may also require extensive
mutagenesis in order to prevent undesired PEGylation where the targeted moiety occurs naturally
in the protein.
Site-specific insertion of unnatural amino acids (uAA) via stop codon suppression offers the
ability to conjugate a protein at potentially any site with minimal mutation [24,94,95]. The wide
variety of uAA with useful side-chain chemistries adds a flexibility to uAA-based conjugation
which makes it a powerful tool for producing optimally PEGylated proteins. However, the optimal
site for PEG conjugation is not well understood and activities of different analogs can vary greatly
[24,40]. In order to mitigate the costs associated with development of optimized PEGylated
proteins, improved guidelines are necessary to inform conjugate design.
E. coli-based cell-free protein synthesis (CFPS) offers an ideal platform for rapidly and
economically screening various sites for uAA incorporation [40,96] and PEGylation, providing a
promising tool for both developing guidelines to inform PEGylated protein design and identifying
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optimal PEGylated proteins from a pool. The flexibility of the CFPS has enabled cell-free synthesis
of a wide variety of challenging proteins, including cytotoxic proteins [33], disulfide-bonded
therapeutics [15], virus-like particles [21,97,98], proteins requiring chaperones [99], and
antibodies [94]. Although the E. coli-based cell-free system is currently unable to replicate
mammalian glycosylation patterns, recent advances in engineering glycosylation into the system
and advances in uAA incorporation are promising developments towards this end. Here we present
a cell-free based approach that allows rapid, scalable assessment of PEGylated proteins, enabling
optimization of PEGylated proteins in a more time- and resource-efficient manner.
As a proof-of-concept study, we apply our system to evaluate existing guidelines for
PEGylated protein design, specifically (1) PEG size and number as a factor in PEGylation
efficiency [79], protein stability [83,87,89,100-102], and protein activity [85,89,103,104]; (2)
PEGylation site solvent accessibility as a predictor of efficient PEGylation [105-108]; and (3)
flexible loops as preferred conjugation sites to minimize stability and activity loss [82,109,110].
Finally, to further enhance the screening process, we also develop a coarse-grain molecular
simulation to inform candidate site selection and demonstrate the utility of the simulation for
coarse PEGylation site assessment.

4.2

4.2.1

Materials and methods

Extract preparation
Extracts were prepared using an Escherichia coli BL21*(DE3) pEVOL-AzF strain, a kind

gift from Peter Shultz [111,112]. The extract was prepared in a manner similar to that which has
been described previously [14,35,37,113,114] with a few modifications. Cells were grown at 37°C
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and 280 rpm in sequential growths. Growths were started in 5 mL of 2xYT media, incubated
overnight, and moved into 100 mL 2xYT. The 100 mL growth was then incubated until an O.D. of
2.0 and then added to 900 mL L 2xYT media in a 2.5 L Tunair baffled shake flask (IBI Scientific,
Peosta, IA) for a final volume of 1 L. When the 1 L growth reached an O.D. between 0.5 and 0.7,
cells were induced with both 1 mL of 1 M isopropyl-1-thio-b-D-galactopyranoside (IPTG) and 0.20
g arabinose. Cells were then monitored and harvested in mid-log phase (an O.D. of ~2.0 in this work)
at 8,000 rpm for 30 minutes. After washing in Buffer A, cells were re-suspended in Buffer A at a
ratio of 1 mL per gram and lysed in three passes through an Avestin Emulsiflex B-15 cell disruptor
(Ottawa, Canada) at 21,000 psi. Lysate was centrifuged at 12,000 rcf for 10 minutes, following
which supernatant was removed and incubated at 37°C for 30 minutes. Extract was then flash frozen
and stored at -80°C until use.

4.2.2

Plasmid preparation
A cysteine-free T4 lysozyme (T4 Lyz) variant was obtained from Addgene (Cambridge,

MA) and cloned into the pY71 plasmid, and a C-terminal strep-tag was added for purification
purposes, as described previously [109]. Six variants – K16Amber, S44Amber, N53Amber,
L91Amber, K135Amber, and Ins163Amber – were created using the Quikchange II mutagenesis
protocol (Agilent Technologies, Santa Clara, CA) [109]. A seventh variant with two Amber codons
was created also using the Quikchange II mutagenesis protocol to insert an additional amber stop
between K162 and N163 on the N53Amber variant. This variant is hereafter referred to as
N53AzF/Ins163AzF. Plasmids were purified for use in cell-free protein synthesis using a Qiagen
Plasmid Maxi Kit (Valencia, CA).
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4.2.3

Cell-Free protein synthesis
Cell-free protein synthesis was performed using the standard PANOxSP system, with a few

modifications [14]. The reaction mixture was as follows, with components obtained from SigmaAldrich unless otherwise specified: 25% v/v E. coli pEVOL pAzF extract, 25% v/v 19-amino acid
PANOxSP mixture (Glutamate was added separately as a salt with Mg in order to optimize the Mg
content of the reaction), 18 mM Mg(Glu)2, 12 nM plasmid purified with Qiagen Plasmid Maxi Kit,
5 μM C14 leucine (PerkinElmer), 3 mM AzF (Chem Impex International, Wood Dale, IL), and the
remaining volume distilled deionized water. For synthesis of the N53AzF/Ins163AzF variant, AzF
was added at 6 mM in order to improve yields. The reactions were assembled under a safe-light and
incubated in darkness in order to preserve the azide group, which decays upon exposure to UV or
near-UV light [14,112,115]. Reactions were performed in 15 mL falcon tubes (GeneMate) at 300 –
400 μL volumes and incubated overnight (~15 hours in this work) at 30°C. Negative control
reactions were performed in 50 μL volumes in 2 mL microcentrifuge tubes (GeneMate) for the same
time at 30°C. Purified synthetase was not added as yields were sufficiently high with only the
synthetase provided in the prepared pEVOL extract. Total protein synthesis yields were determined
using liquid scintillation as discussed previously [14], using 5% trichloroacetic acid for protein
precipitation. Synthesis of full-length protein was verified by running 3 μL of the CFPS reaction on
a NuPAGE 10% Bis-Tris Gel (Invitrogen, Carlsbad, CA). The gels were run according to
manufacturer’s instructions, at 200V for 35 minutes using MES buffer. After running, gels were
stained with SimplyBlue SafeStain (Invitrogen), dried, and autoradiograms were performed using
Kodak MR Autoradiogram Films with 2 day exposure time. Yields of full-length variants were
determined from densitometry using ImageJ software [116] to compare the relative band intensities
to that of WT lysozyme and scale the yields accordingly to the WT yields.
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4.2.4

T4 lysozyme purification
T4 Lyz was purified using Strep-Tactin Spin Columns (IBA Life Sciences, Gottingen,

Germany) according to manufacturers’ specifications, with the following variations. To improve
recovery, CFPS samples were run through the spin columns three times and columns were then
washed 5 times with the provided Buffer W. T4 Lyz was then eluted according to the procedure
specified for high concentration. Liquid scintillation was used to determine the concentration of
the purified product. Using the total protein yields calculated from the scintillation of the CFPS
reaction, the CPM/mg/mL was determined for each sample, which was then used to calculate the
concentration of T4 Lyz variant in the purified samples.

4.2.5

PEGylation reactions
Conjugation reactions were performed using strain-promoted azide-alkyne cycloaddition, or

SPAAC. The number of PEG equivalents was optimized to obtain maximal conjugation with the
minimal allowable PEG. The optimal PEG equivalents was determined to be 20 for 20kDa PEG and
50 for 5kDa PEG. Reactions were assembled similarly to protocols which have been described
previously [117,118], with the following specifications. In a PCR tube, 5 μM T4 lysozyme was
combined with 20 or 50 equivalents of 20kDa or 5kDa DBCO-mPEG (Click Chemistry Tools,
Scottsdale, AZ), respectively, in PBS buffer. PEG equivalents were doubled for the double amber
suppression variant in order to obtain higher conjugation efficiency. The reactions were incubated
at 37°C and 280 rpm for 18 hours. Although complete conjugation with SPAAC reactions has been
reported with much shorter reaction times [94,118], an 18 hour reaction time was used to maximize
conjugation at low-efficiency sites and thereby obtain more accurate stability and activity data for
these T4 Lyz analogs. Control reactions were also assembled with WT T4 Lyz, mimicking the
conditions of the SPAAC reactions for both PEG sizes and unconjugated controls. These reactions
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provided a baseline to account for the effects of incubation time and unconjugated PEG on the
stability and activity of the lysozyme.

4.2.6

PEGylation efficiency analysis
To determine efficiency of each PEGylation reaction, a sample of each reaction was run on

a NuPAGE 10% Bis-Tris Gel at 200V for 35 minutes using MES buffer. The gels were stained with
SimplyBlue SafeStain (Invitrogen), dried, and used to produce an autoradiogram. Autoradiograms
were produced using Kodak MR Autoradiogram Film with a 2 day exposure. Using ImageJ, the
relative intensities of the PEG-shifted bands and the un-shifted bands were calculated. The click
efficiency was determined as the intensity of the PEG-shifted band divided by the sum of the
intensity of the un-shifted and shifted band(s) in the gel lane. PEGylation efficiencies were calculated
from the autoradiogram to eliminate error from possible interference of PEG with staining.

4.2.7

Stability analysis

4.2.7.1 Stability assay
Stability was analyzed by examining the shifts in the protein melting temperature, Tm.
Melting temperatures were determined using the Protein Thermal Shift Assay (Thermo Fisher
Scientific, Carlsbad, CA) and the corresponding Protein Thermal Shift Software, version 1.3. This
assay uses a hydrophobic dye which fluoresces when it binds to the hydrophobic regions of the
protein as they are exposed during melting. The protein is combined with the dye and gradually
stepped through increasing temperatures in a real-time PCR machine, which monitors the change in
florescence. The florescence curve is then used to determine the melting temperature. Melting
temperatures were calculated using the derivative method to avoid skewing of a Boltzmann fit by
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any remaining peak for the unconjugated protein. The derivative method identifies the Tm by
computing a second-derivative to identify the inflection point of the fluorescence curve.
The melt reactions were assembled according to the manufacturer’s instructions, with the
following specifications: 5 μL Protein Thermal Shift Buffer, 7.5 μL PBS buffer, 5 μL click reaction,
2.5 μL Diluted Protein Thermal Shift Dye (8x) diluted with PBS buffer. Reactions were carried
out in triplicate, assembled in a 96-well, semi-skirted Framestar Fast Plate (Midsci, St. Louis, MO)
and covered with a MicroAmp Optical Adhesive Film (Applied Biosystems,Thermo Fisher
Scientific). The assay was set up using StepOne Software v2.3, and run in a StepOnePlusTM RealTime PCR System (Applied Biosystems). In order to obtain maximal resolution of the Tm, the
assay was run using a standard ramp speed from a starting temperature of 25°C to 99°C. Analysis
was done using the derivative method. Results are reported as a change from the average Tm of the
corresponding WT reaction (no PEG, 5kDa PEG, or 20kDa PEG), ΔTm. For the simulation
comparison, the experimental data is reported as a difference in Tm between a PEGylated T4 Lyz
variant and the corresponding unconjugated variant, ΔTm,conj.
4.2.7.2 Simulation-predicted Tm
Coarse-grain simulations were performed using the Go-like model and replica-exchange
algorithm which has been described previously [119-122]. In this coarse-grain model, each residue
is approximated as a single site, centered at the location of the Cα atom of the residue in the crystal
structure.

The

model

input

files

were

created

using

the

MMTSB

Web

Service

(mmtsb.org/webservices/gomodel.html) [123,124] based on the T4 Lyz structure from the Protein
Data Bank (PDB ID: 2LZM). PEG monomers were approximated as single residues with a radius of
1.48 angstroms and a center-to-center distance of 3.7 angstroms, and the DBCO connecting group
was approximated as a residue with a radius of 5.18 angstroms. These distances were obtained using
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a GaussView [125] model of the SPAAC product and attached PEG chain. Bond energies were also
obtained from GaussView [125]. Other relevant parameters, including Lennard-Jones parameters,
were chosen to resemble those of the peptide bonds within the protein. Additional details pertaining
to the model form are included in Appendix C section C.1.
PEG chains were added to the protein model extending linearly away from the attached site.
The PEG chain was then allowed to equilibrate to a more realistic conformation in NVE MD
equilibrium simulations with constraints in place to hold the protein in the properly folded
conformation while the PEG polymer equilibrated. Results of these equilibration simulations were
then used as starting points for replica exchange simulations where an additional unconstrained
equilibrium phase ensured system equilibration before production steps were recorded. Replica
exchange simulations were done in the NVT ensemble using three Nose-Hoover thermostats, a time
step of 3 fs, and a mass of 7.81338x10-22 kg*angstroms2. Each simulation contained 20 x 106
equilibration steps and 60 x 106 productions steps. Sixty-six boxes, with temperature steps of 1.5K
between boxes in the 21K range surrounding the expected melting temperatures (345K – 366K for
5kDa conjugates, 327K – 348K for WT and 20kDa conjugates) and steps of 3K for the remaining
range, were used for all simulations with a box size of 4000 x 4000 x 4000 angstroms. The replica
exchange simulations were run 10 times for all cases except for K16 and S44 PEGylation models,
which were run 20 times due to slightly more scatter in the data. The results for all runs were
averaged and the standard error reported.
The average relative native contacts, representing the remaining interactions pertaining to
the protein secondary and tertiary structure relative to the 100% folded state, was plotted versus
temperature. This plot shows how the degree of protein folding decreases over temperature as the
protein unfolds, and is analogous to the fluorescence versus temperature plot obtained from the
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experimental assay. To mimic the experimental analysis, the derivative of the relative native contacts
was calculated numerically with respect to temperature using a central difference formula. The
temperature at which the magnitude of this derivative was greatest was taken to be Tm, as it
represents the point where the rate of change in the degree of protein folding is greatest, and
corresponds with the point where the rate of increase in fluorescence is greatest. This point also
corresponded with the maximum heat capacity value, which is expected as Tm is also often
determined to be the temperature at which heat capacity is a maximum. The melting points calculated
from simulation were then compared to the experimentally determined Tm.

4.2.8

Activity assay
Activity of each lysozyme construct was determined via the EnzChek Lysozyme Assay Kit

(Thermo Fisher Scientific). Reactions were performed according to the manufacturer’s instructions,
with the following specifications and modifications. EnzChek buffer was not used, as it has been
reported that T4 Lyz is less active at high ionic strengths [126]. Unpurified PEGylated lysozyme
from each SPAAC reaction was added to each reaction at a final lysozyme concentration of 0.06
μM. This lysozyme concentration was selected because it did not cause the activity assay to saturate
and required less dilution than other suitable concentrations, which eliminated unnecessary error. In
a black 96-well untreated polystyrene plate (VWR), 1.2 μL of unpurified SPAAC reaction was added
to 48.8 μL ddH2O and mixed thoroughly by pipetting. The 1 mg/mL fluorogenic substrate was
diluted 20x in ddH2O, and 50 μL was added to each well. The plate was then immediately placed
into a plate reader (Synergy MX, BioTek) and incubated at 37°C. Fluorescence was monitored every
1.5 minutes for 2 hours (494nm/518nm). Activity was determined from the endpoint fluorescence
of each well and normalized to the endpoint activity of the corresponding WT reaction. Each sample
was assayed in n=3+. Relative activity of each PEGylated lysozyme analog was calculated from the
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mixture activity data, assuming additive activities of the PEGylated and unPEGylated lysozyme.
WT activity data for a set of assays was averaged, and then conjugate activity (ac) was calculated for
each replicate according to Equation 4-1, where xc and xuc is the fraction of conjugated and
unconjugated T4 Lyz, respectively, arxn is the activity of the reaction mixture, and auc is the activity
of the unconjugated variant. The activity for di-PEGylated N53AzF/Ins163AzF (ac2) was calculated
as shown in Equation 4-2, where the activity of mono-PEGylated N53AzF/Ins163AzF (ac1) is
calculated as shown in 4-3, where aN53AzF,c and aN53AzF,uc is the activity of conjugated and
unconjugated

N53AzF,

respectively,

with

analogous

activities

for

Ins163AzF

and

N53AzF/Ins163AzF. Calculated activities were then averaged over all replicates and over all sets of
assays.
(4-1)

𝑎𝑎𝑐𝑐 = 1/𝑥𝑥𝑐𝑐 ∗ (𝑎𝑎𝑟𝑟𝑟𝑟𝑟𝑟 − 𝑥𝑥𝑢𝑢𝑢𝑢 𝑎𝑎𝑢𝑢𝑢𝑢 )

(4-2)

𝑎𝑎𝑐𝑐2 = 1/𝑥𝑥𝑐𝑐2 ∗ (𝑎𝑎𝑟𝑟𝑟𝑟𝑟𝑟 − 𝑎𝑎𝑢𝑢𝑢𝑢 𝑥𝑥𝑢𝑢𝑢𝑢 − 𝑎𝑎𝑐𝑐1 𝑥𝑥𝑐𝑐1 )

𝑎𝑎𝑐𝑐1 = 0.5 �

4.3

4.3.1

𝑎𝑎𝑁𝑁53𝐴𝐴𝐴𝐴𝐴𝐴,𝑐𝑐

𝑎𝑎𝑁𝑁53𝐴𝐴𝐴𝐴𝐴𝐴,𝑢𝑢𝑢𝑢

+

𝑎𝑎𝐼𝐼𝐼𝐼𝐼𝐼163𝐴𝐴𝐴𝐴𝐴𝐴,𝑐𝑐

𝑎𝑎𝐼𝐼𝐼𝐼𝐼𝐼163𝐴𝐴𝐴𝐴𝐴𝐴,𝑢𝑢𝑢𝑢

� ∗ 𝑎𝑎𝑁𝑁53𝐴𝐴𝐴𝐴𝐴𝐴/𝐼𝐼𝐼𝐼𝐼𝐼163𝐴𝐴𝐴𝐴𝐴𝐴,𝑢𝑢𝑢𝑢

(4-3)

Results and discussion

CFPS-based screening system
In this study we first seek to demonstrate the utility of a cell-free expression system to

quickly assess the impact of PEG size and conjugation site on the properties of a target protein.
Using CFPS as opposed to in vivo methods reduced resource costs and accelerates protein
preparation from weeks to days by (1) eliminating cell culturing of each protein variant, enabling
protein synthesis in ~8 hours, (2) allowing microliter scale protein synthesis reactions for efficient
reagent use, and (3) simplifying protein purification. Additionally, in less than 5 hours and with
less than 2 μg of each protein sample, we are able to screen PEGylation efficiency and thermal
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stability in parallel with protein activity. We selected T4 lysozyme (T4 Lyz, EC 3.2.1.17) as a
model enzyme for this study, and at the conclusion of our study, we evaluate our results against
several generic PEGylation guidelines.
4.3.1.1 CFPS of screening pool
Six sites were selected for uAA p-azido-L-phenylalanine (AzF) incorporation, spanning a
range of solvent accessible surface areas (SASA) and structures. The selected sites are as follows:
substitutions at sites K16, S44, N53, L91, and K135, and an amber stop insertion between residues
K162 and N163 (Ins163). Locations of the selected sites along with their corresponding relative
SASA values, as scored by ASA-View [127], are reported in Figure 4-1A. Plasmids were
constructed to incorporate the amber stop codon, TAG, at each of these sites, as detailed in section
4.2.2.
We also constructed a double amber suppression variant, as di-PEGylation may further
stabilize proteins compared to mono-PEGylation [87] [128], Di-PEGylation may also provide
additional advantages for therapeutic proteins, such as reduced vacuole formation in the kidneys
[129]. We constructed a double amber suppression variant with sites N53 and Ins163 (N53/Ins163),
because they have high solvent accessibility and are located on opposite sides of the protein.
Using an E. coli-based cell-free system, AzF was incorporated as reported previously [14],
resulting in the production of the following lysozyme variants: K16AzF, S44AzF, N53AzF,
K135AzF, Ins163AzF, and N53AzF/Ins163AzF. As our lab and others have observed previously
[24,40,130], yields of full-length lysozyme varied depending on the location of uAA incorporation.
Average yields fell between 160-500 μg/mL (Figure 4-1B) – exceeding 25% of wild-type (WT)
yield in all cases – and very low levels of full-length T4 Lyz expression were observed in the
absence of AzF. The yield of the double-AzF-modified protein was 0.28 mg/mL, significantly
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exceeding previously reported yields for double AzF-incorporation via amber suppression
[104,107,110]. The ability to achieve higher yields in hours, even for double amber suppression,
is a primary advantage of the CFPS expression system as a basis for a conjugate screening platform.
Full-length AzF-incorporated variants were then rapidly purified using spin columns, as detailed
in section 4.2.3.
Using the cell-free system enables sufficient protein yields for our screen from ≤ 400 μL
reactions in just 8+ hours with minimal optimization. As such, CFPS reduces time and resource costs
of the screen by eliminating the need for cell culturing of each construct. This system also simplifies
purification by eliminating the lysis and clarification steps between expression and purification,
allowing direct addition of the expression reaction to a spin column for rapid, small-scale
purifications.

Figure 4-1: T4 Lysozyme Variants and Yields. (A) ASA-View relative solvent accessible surface areas,
normalized to the average surface area of each amino acid in 30 random configurations of a Gly-X-Gly
tripeptide (*SASA reported for Ins163 insertion site is an average of the ASA-View values for the SASA
of K162 and N163), and Chimera image showing locations of these residues in T4 Lyz (PDB ID: 2LZM).
Residues depicted in green are part of unstructured loops, while structured sites are represented in pink or
orange (pink for beta sheet, orange for alpha helix). The residues surrounding the insertions site are shown
in yellow, and are also part of an unstructured loop; (B) Full-length T4 Lyz CFPS yields and autoradiogram.
Data shown are averages and standard deviations of n ≥ 2.
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4.3.1.2 PEGylation efficiency screening
Purified T4 Lyz variants were PEGylated with 5kDa and 20kDa PEG using a strain-promoted
azide-alkyne cycloaddition (SPAAC) reaction. The SPAAC reaction, illustrated in Figure 4-2A, is
advantageous because it can be done rapidly and at physiological conditions without additional
components such as protecting groups or copper catalysts [14,131,132]. SPAAC reactions were
performed using 5 μM purified T4 Lyz variant and 20 or 50 equivalents, respectively, of 20kDa or
5kDa PEG with a dibenzocyclooctyne (DBCO) terminal group providing the strained alkyne DBCOmPEG. The DBCO-mPEG equivalents were doubled for PEGylation of N53AzF/Ins163AzF. These
conditions provided high click efficiency at most of the chosen sites.

Figure 4-2: PEGylation Reaction Scheme and Efficiency. (A) Illustration of the SPAAC reaction used for
PEGylation where DBCO-mPEG and AzF-substituted T4 Lysozyme are covalently conjugated; (B)
PEGylation efficiency of T4 lysozyme variants (n ≥ 2, error bars represent one standard deviation, p values
are reported for each variant comparing the 5kDa to the 20kDa PEGylation efficiency and p > 0.05 in all
cases); (C)PEGylation efficiency vs relative SASA, note that relative SASA does not appear to be linearly
correlated with conjugation efficiency in this study (n ≥ 2, error bars represent one standard deviation and
are hidden under marker when not visible). Dashed lines represent a linear regression, with the orange line
fit to the 5kDa PEG data and the gray line fit to the 20kDa PEG data. The corresponding R2 values are also
reported.
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Average PEGylation efficiency is shown in Figure 4-2B as calculated by SDS-PAGE
electrophoresis, autoradiography, and densitometry (Figure 4-3). As alluded to previously, the
conjugation sites selected in this study were chosen in part to evaluate PEG size and conjugation site
accessibility, which are common guidelines for the design of PEGylated proteins with high
conjugation efficiency [79,105-108]. The results of our screen revealed no significant impact of PEG
size on click efficiency with the 5kDa and 20kDa unbranched-PEG molecules employed in our study,
even for the di-PEGylated N53AzF/Ins163AzF (Figure 4-2B). This result suggests that the
accessibility of the site to the larger DBCO group plays a stronger role in conjugation efficiency than
the 15kDa increase in size of the flexible PEG chain. Indeed, the impact of PEG size on PEGylation
efficiency may be influenced by the conjugation mechanism, and this possible relationship should
be considered when optimizing PEGylation location. We also observed that while the fraction of
unmodified N53AzF/Ins163AzF following SPAAC reaction is on par with that of N53AzF and
Ins163AzF, the efficiency of dual PEGylation is lower than would be expected based on the
conjugation efficiencies of each site individually (expected: 62%, 63%). These results suggest that
steric hindrance from the first PEG chain may inhibit conjugation with the second PEG chain, despite
the relatively large distance between the sites, and is an important factor when considering the
advantages of multi-PEGylation verses mono-PEGylation with longer PEG. This phenomenon is
expected based on observations for dual-PEGylation using natural amino acids [129].
Using our screen, we also found that higher SASA does not necessarily correlate with higher
conjugation efficiency (Figure 4-2C). Using Chimera [133], we also evaluated the local surface
hydrophobicity of these sites, a trait which has been suggested to improve SPAAC efficiencies via
interaction with the hydrophobic DBCO group [108,134]. Again, we found no clear correlation
(Figure 4-4), suggesting that neither SASA nor local surface hydrophobicity are sufficient predictors
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of high-efficiency conjugation sites. The discrepancies between common design guidelines and our
results as described above further demonstrate the need to rapidly screen multiple PEGylation sites
in parallel. Importantly, the small-scale expression reactions and low concentration conjugation
reactions described above mitigate screening costs by reducing the amount of product needed.

Figure 4-3: Sample SDS-PAGE and Autoradiogram of SPAAC Reactions for Click Efficiency analysis.
(Left) 10% Bis-Tris gel of SPAAC samples (6 µL each) run against Unstained Protein Marker, Broad Range
(2-212 kDa) (P7702, NEB). Lanes: 1-K135, 2-K135 + DBCO-PEG5kDa, 4 - K135 + DBCO-PEG20kDa,
6 - Ins163AzF, 7 – Ins163AzF+DBCO-PEG5kDa, 9 – Ins163AzF + DBCO-PEG20kDa, 11 – N53AzF/
Ins163AzF, 12 - N53AzF/ Ins163AzF + DBCO-PEG5kDa, 14 - N53AzF/ Ins163AzF + DBCO-PEG20kDa;
(Right) autoradiogram of gel shown on the left, exposed for 4 days.

4.3.1.3 Stability screening
A primary motivation for PEGylating proteins is to improve both thermal stability and
protease resistance [87,89,135]. Hence, stability evaluation is a key step in the conjugate screening
process. Stability against protease degradation has previously been shown to correlate with protein
conformational stability [87]. Thus, in our screening approach we use changes in protein melting
temperature to characterize the stability of the screened proteins and corresponding conjugates.
Thermal shift assays provide a higher-throughput, more cost-effective method for assessing
protein melting temperature when compared to more traditional methods such as differential
scanning calorimetry by allowing rapid, accurate Tm characterization with small samples and lowcost reagents. Here, we use a protein thermal shift assay to evaluate stability of our screening pool
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using only 1-1.5 μg protein from each unpurified SPAAC reaction (3 replicates with ~0.3-0.5 μg
of protein per replicate) in under 5 hours at less than $0.30 per screened protein or conjugate (~
$ 0.09 per replicate). The Protein Thermal Shift assay requires three orders of magnitude less
protein at an order of magnitude lower protein concentration than traditional differential scanning
calorimetry [136].
Using the Protein Thermal Shift assay, control Tm values for WT, WT+PEG5kDa, and
WT+PEG20kDa were determined to be 61.0°C ± 0.10, 61.1°C ± 0.81, and 60.7°C ± 0.39,
respectively, at a pH of 7.4, which agrees well with values previously reported for WT T4
lysozyme in literature [137-141]. The change in Tm due to incorporation of AzF or PEGylation at
the incorporated AzF residue(s) relative to the corresponding control WT Tm is shown as ΔTm in
Figure 4-5A.
For all seven lysozyme variants, the magnitude of ΔTm associated with AzF incorporation
was greater than the magnitude of the change in ΔTm as a result of PEGylation (Figure 4-5A, blue
bars vs the difference between blue bars and either orange striped or white bars. This change in
ΔTm between the conjugated and unconjugated T4 Lyz variants will be referred to as ΔTm,conj,
where ΔTm,conj = ΔTm,PEGylated - ΔTm,unconjugated). The observed impact on stability of even a single
amino acid change demonstrates the challenge of engineering conjugation sites into proteins, as
even minimal mutation can cause significant impact on protein stability. This further highlights
the utility of the presented CFPS-based conjugate screening approach, as cell-free systems have
been used to corporate a variety of uAAs [14], providing an opportunity to minimize the impact
on stability through optimization of the choice of uAA.
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Figure 4-4: Hydrophobicity Surfaces for T4 Lyz. Blue areas are hydrophilic, white areas are neutral, and
orange areas are hydrophobic. Surfaces of residues targeted are transparent, showing the side chains of the
native residues underneath. Green labels/arrows indicate a conjugation site that conjugated very efficiently,
yellow labels/arrows indicate a conjugation site that conjugated efficiently, and red labels/arrows indicate
a site which conjugated inefficiently. (A) surface in vicinity of residue K16; (B) surface in vicinity of
residue S44; (C) surface in vicinity of N53; (D) surface in vicinity of residue L91; (E) surface in vicinity of
residue K135; (F) surfaces in vicinity of residues K162 and N163. Generated using Chimera [133] (PDB
ID 2LZM).

PEGylation had the greatest stabilizing impact on K16AzF and Ins163AzF, but modestly
improved the stability at all mono-AzF T4 Lyz variants with the exception of L91AzF. Slight
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improvements in stability following double PEGylation of N53AzF/Ins163AzF were not significant,
indicating that in this case stabilizing benefits did not compound as previously reported [87]. The
varying impact of PEGylation on Tm for the different T4 Lyz variants was also not well predicted
by SASA (Figure C-1).
In all cases, increasing PEG size from 5kDa to 20kDa did not affect the protein stability
(Figure 4-5A), which agrees with many previous reports [100-102]. Studies which have found
increased conjugate thermal stability with increasing PEG size have focused on smaller PEG
oligomers [87,142], which could explain the difference to the present study (see Appendix C section
C.2 for a more detailed discussion).
Our data also indicate that unstructured sites are not necessarily preferable to structured sites,
either for uAA substitution or for PEGylation. Indeed, the site which was most tolerant of the AzF
substitution was S44, which is located inside an alpha helix. By contrast, the least tolerant site, L91,
is in an unstructured loop just outside an alpha helix. Similarly, the K16AzF variant was most
stabilized by PEGylation, despite its location in a beta sheet. In contrast, PEGylation at an alpha
helix (S44AzF) or at less structured sites was less stabilizing.
The dramatic destabilization from PEGylation at site L91 is interesting, given that this site
was determined to be the optimal site for lysozyme immobilization [109,119]. These results indicate
that the effects on protein stability from conjugation to a polymer differ significantly from the effects
due to conjugation to a surface. A more detailed discussion of these differences is contained in
Appendix C section C.2.
Overall, our results highlight the need for screening approaches such as the one presented
herein due to the lack of predictive factors for PEGylation-based stabilization. The CFPS-based
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screening approach provides a method for rapid, cost-effective screening of the effect of PEGylation
at a variety of sites on protein thermal stability.

Figure 4-5: T4 Lysozyme Stability and Activity Before and After PEGylation. (A) Thermal stability of T4
Lyz variants and conjugates. ΔTm is determined as Tm – Tm,control, where Tm, control is for WT T4 Lyz;
(B) Relative activity of T4 Lyz variants and conjugates; (C) Relative Activity vs ΔTm. Data from A and B
plotted against each other. For A and B, data is shown as averages with one standard deviation, where n n
≥ 3, and stars indicate significant differences, where *** = p < 0.001 and ** = p < 0.01.

4.3.1.4 Activity screening
Retained protein activity is another essential metric in the design of PEGylated protein.
Fortunately, a reduction in specific activity following PEGylation can be compensated for, in many
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cases, by a corresponding increase in stability [79]. However, minimizing the negative effects of
PEGylation on activity would require less PEGylated protein in its final application, reducing costs
and negative side effects of therapeutics. As PEG size and number have been previously reported to
impact the activity of PEGylated proteins, we applied our screen to evaluate these effects on T4 Lyz
activity [85,89,103,104]. The activity of each T4 Lyz variant and its PEG5kDa and PEG20kDa
conjugates was determined using the Enzchek Lysozyme Assay (ThermoFisher Scientific) as
reported in Figure 4-5B.
The activities of unconjugated K16AzF, S44AzF, N53AzF, K135AzF, and Ins163AzF were
not statistically different (p > 0.05). However, all are greater than the activities of L91AzF and
N53AzF/Ins163AzF. These results suggest that, like stability, activity of AzF substituted variants
are not well predicted by modification site secondary structure. The reduction in the activity of the
unconjugated N53AzF/Ins163AzF was less than the sum of the reductions from the two individual
AzF incorporations (N53AzF and Ins163AzF), suggesting that the activity losses in multi-uAA
incorporations should not be considered additive. L91AzF had the lowest activity of any
unconjugated T4 Lyz variant, including the double amber suppression variant, at only 61% WT
activity.
Of the six mono-PEGylated lysozyme variants tested, only PEGylation of N53AzF clearly
increased the activity. While unexpected, improved activity following PEGylation is not without
precedent [83,143]. PEGylation at both the structured sites K16AzF and S44AzF and at the
unstructured sites K135AzF and Ins163AzF did not significantly change the activity compared to
the unconjugated variants. This suggests that the effect of PEGylation on activity is not well
predicting by conjugation site secondary structure.
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In stark contrast to the other five mono-PEGylated variants, PEGylation of L91AzF resulted
in an additional loss of activity, with conjugates retaining only about 60% of the activity of
unconjugated L91AzF. This decrease in activity correlates with the significant decrease in stability
seen as a result of PEGylation of L91AzF. There may be a general correlation between high activity
retention and SASA, given the reduction in activity following PEGylation of L91AzF, minimal
impact of PEGylation on activity for K16AzF and S44AzF, and improvement in activity following
PEGylation of N53AzF. However because only PEGylation of L91AzF and N53AzF significantly
changed the activity, the utility of the trend in predicting sites with the highest activity retention is
uncertain (Figure C-2). Still, SASA could be a useful guideline in narrowing potential PEGylation
sites to exclude sites with very low SASA.
In addition, activity of diPEGylated N53AzF/Ins163AzF decreased with 20kDa PEG. As
neither PEGylation of N53AzF nor Ins163AzF with 20kDa PEG had a negative effect on activity,
and because PEGylation of the double amber suppression variant had no significant effect on the
stability of the variant, this decrease in activity can reasonably be attributed to reduced accessibility
of the active site to the macromolecular substrate (Micrococcus lysodeikticus cell walls) due to steric
hindrance from the two large PEG chains.
In all cases, there was no significant difference between the activities of the 5kDa PEG
conjugates vs the 20kDa PEG conjugates. PEG size has previously been reported to be negatively
correlated with in vitro activity [85,89,103,144], but other studies have also shown that in some
cases activity is independent of PEG size [145,146]. For example, another study in which IFN was
PEGylated with 5kDa, 10kDa, and 20kDa PEG at a disulfide bridge and the activity impact was
found to be size independent [146].
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Literature also reports that point mutations in a protein have minimal, localized impact on
the structure [140], so, given their distance from the active site, it is less likely that any of these
mutations impact activity by deforming the active site. Thus, it is reasonable that any changes in
activity would be related to changes in the dynamics of the protein. In analyzing the data in this
study, there indeed appears to be a correlation between T4 Lyz analog stability and activity, as shown
in Figure 4-5C. This relationship between stability and enzymatic activity could be used as a
screening tool to eliminate variants which are likely less active based on their stability. This would
reduce costs of PEGylation screening, as activity assays are more expensive than the stability assay.
It is important to note that more data is necessary to confirm the existence of this trend for proteins
beyond T4 Lyz, however, the presented screen could facilitate verification of this trend for other
proteins. Verification of this trend would be especially important for proteins with more than 2
folding states, as destabilization of certain domains may have a smaller impact on activity than others.
However, our study indicates that stability could be a useful metric by which to eliminate less active
candidates in a large screen without directly testing the activity of all candidates.

4.3.2

Evaluating common PEGylation guidelines with experimental screen results
In the decades since the introduction of PEGylation, several recommendations have evolved

towards the design of PEGylated proteins. A synopsis of key similarities and differences between
the effects of PEGylation observed experimentally through the present screen and some common
PEGylation guidelines in literature is summarized in Table 2-1.
Our observations regarding PEG size support the claim that, in general, large PEGs are more
advantageous than small PEGs for conjugate optimization, as we found no significant negative
impacts of PEG size on the stability or activity of T4 Lyz which might offset the improved
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pharmacokinetics generally reported for conjugates with larger PEG chains [129,147-149]. In our
evaluation of in vitro assays of a double site-specifically PEGylated conjugate, we found no
motivation for double site-specific PEGylation due to the lack of additional stabilizing benefit and
the negative effects on activity. However, as it is well documented that increased PEG weight
improves pharmacokinetics of a therapeutic, these results suggest that there may be an optimal tradeoff between specific activity and half-life which could potentially be achieved through double sitespecific PEGylation. Finally, we evaluated trends in click efficiency, activity, and stability relating
to the uAA incorporation/PEGylation site, finding that current design metrics were insufficiently
predictive of the effects of PEGylation observed through our screen.
Overall, the experimental screen enabled the identification of S44, followed closely by N53,
as the best sites for PEGylation of the sites screened due to their high PEGylation efficiency, high
thermal stability, and high retention of activity. It should be noted that PEGylation had the greatest
stabilizing effect on K16AzF, K135AzF, and Ins163AzF, however these sites were less tolerant of
the AzF incorporation and had lower conjugation efficiencies. The locational effects of site-specific
PEGylation were not well predicted by the common design guidelines evaluated in the screen. While
some guidelines, such as conjugation at sites with high SASA, may have merit in some aspects of
PEGylation engineering, their predictive capacity is incomplete. For example, K135 may be
correctly predicted by SASA to have high activity retention, however PEGylated K135AzF would
be more costly to produce commercially than similarly active S44AzF due to its low PEGylation
efficiency. Hence, the screening approach presented is an attractive tool to facilitate the efficient
screening of PEGylation sites in order to optimize the multiple facets of PEGylated protein design.
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Table 4-1: Comparison to PEGylation Design Recommendations in Literature.
PEGylation Design Facet

PEG Size

PEG Number

Efficiency

Conjugation
Site

PEGylation Recommendations in
Literature
- Larger PEGs offer improved
pharmacokinetics and stability relative to
smaller PEGs [83,89]
- ΔTm independent of PEG size [100-102]
- In vitro activity is inversely proportional
to attached PEG mass [85,89,103,104]
- Higher modification number correlates
with lower activity [85]
- PEGylation at two individually
stabilizing sites results in further stability
improvement [87]
- Single large PEG is preferable to
multiple small PEGs [89]
- High SASA (Residues with ASA-View
score > 0.4) improves conjugation
efficiencyg[105-108]
- Buried residues in hydrophobic pockets
may conjugate with high efficiency in
SPAAC reactions [108]
- Conjugation at unstructured loops may
minimize the strain on protein structure
[82,109,110]

Stability/
Activity

4.3.3

Observations with CFPS Screen
- No significant difference in
stability or activity of 20kDa
conjugates vs 5kDa conjugates

- Double PEGylation with 20kDa
PEG decreased activity slightly
- Double PEGylation at two
individually stabilizing sites did
not significantly improve
stability
- SASA was not predictive of
conjugation efficiency
- No clear correlation to surface
hydrophilicity/hydrophobicity
- No clear correlation between
stabilizing potential and
PEGylation site secondary
structure or SASA.
- General trend of increased
activity retention after
conjugation at higher SASA
may help to narrow
experimental screens by
eliminating sites with very low
SASA

Enhancing CFPS-based screen with coarse-grain simulation
Considering the necessity of an experimental screen, an in silico tool to narrow candidate

PEGylation sites would be useful in further reducing the costs of PEGylated protein design. Protein
stability is a driving factor in protein PEGylation and is highly dependent on PEGylation site,
therefore we sought to integrate a rapid molecular dynamics simulation as part of the screening
process. Specifically, the potential of coarse grain simulation was evaluated as a pre-screen tool to
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inform selection of candidate conjugation sites, thereby reducing the size of the screening pool.
Coarse-grain molecular dynamics simulations have previously been used to correctly identify an
optimal site for T4 Lyz immobilization [109,119]. The method employs replica exchange
molecular dynamics to calculate the heat capacity (Cv) of the molecule as a function of temperature.
Peaks in the Cv curve occur during structural transitions (unfolding/folding), and changes in the
thermal stability can be obtained by comparing the temperatures at which the peaks occur in the
Cv profiles of WT T4 Lyz and PEGylated T4 Lyz (Figure C-3 and Figure C-4). The computational
efficiency of coarse-grain, molecular simulation make it especially appealing as a screening tool
because many simulations can be done quickly and in parallel.
We modified the coarse-grain simulation to include a conjugated PEG chain at a specified
site. The methods used are those that have been outlined previously [119-122] with a few
modifications to include PEG, as detailed in the Materials and Methods. While the mechanism
behind PEG-based stabilization is not well understood, there are two primary theories: PEG
stabilizes proteins through (1) direct interaction with the protein surface [142,150,151] or (2)
entropic interactions with the solvent [87,150]. In this study we limited the simulation to evaluate
only the entropic effect. The entropy-only approach has been successfully applied to immobilized
proteins [120,152], and it has been previously reported that the stabilizing effect of PEG is
primarily entropic [87]. The polymer-protein interactions were thus purely repulsive. The tethering
of PEG to the protein was done with a simple harmonic restraint without changing the tethering
residue to AzF. Currently AzF cannot be included in the model due to insufficient experimental
data for parametrization of AzF in the coarse-grain interactions. Therefore, predicted changes in
melting temperature correspond to the change in melting temperature solely due to PEGylation
(ΔTm,conj). The three-dimensional structure of T4 Lyz, needed for the model, was obtained from
63

PDB ID 2LZM and is expected to be a reasonable representation of the structures of AzFsubstituted lysozyme as any structural perturbations resulting from such substitutions have been
previously reported to be minimal and highly localized [140]. However, we excluded the variants
involving an AzF insertion (Ins163AzF and N53AzF/Ins163AzF) from the simulation due to
concerns that the WT structure may be a less accurate representation of the structure for these
variants.
We compared the simulation-predicted ΔTm,conj to the experimentally determined values
in our screen, with the results shown in Figure 4. The predictions from the entropy-based
PEGylated T4 Lyz simulations agree well with the results from experiment. While the simulation
did not predict the exact change in melting temperature due to PEGylation, it accurately predicted
the relative change in stability after PEGylation. For both the PEG5kDa and PEG20kDa, the
simulation accurately predicted the most stabilizing site for conjugation to be residue 16 and the
least stabilizing site to be residue 91. The simulation also accurately predicted the remaining 3
sites to be slightly less stabilizing than conjugation at residue 16 but significantly more stabilizing
than conjugation at site 91. As such, the entropy-only simulation could be a powerful tool for
informing design of a screening pool. Adapting the simulation to include enthalpic effects of PEGprotein interactions may further improve the predictive capacity of the simulation. Indeed,
previous results have suggested that the enthalpic interaction effects of PEGylation can be
destabilizing in some cases [87], which could account for the over-prediction of ΔTm,conj by the
entropy-only model. Interestingly, the simulation seems to provide better quantitative estimates of
ΔTm,conj for the 20kDa conjugates. We hypothesize that this is due to a more dominant impact of
entropy with the larger polymer. Hence, incorporation of PEG-protein interaction parameters may
also allow the model to predict the relative impact of PEGylation with different lengths of PEG.
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Overall, our use of coarse grain simulations indicates that valuable insight can be gained
about comparative effects of PEGylation from a simple, entropy-based model. This model could be
incorporated as part of the screening process to create a hybrid simulation- and experimental-based
screening method in which all of the sites on a target protein which are available to conjugation are
first screened with the coarse grain model. The simulations in this study ran to completion in under
11 hours, potentially enabling simultaneous evaluation of all potential conjugation sites on a protein
in less than 24 hours. Sites which are predicted by the simulation to be least stabilizing could then
be eliminated from the subsequent experimental screen in order to conserve resources by reducing
the number of candidate conjugation sites. Further improvements in the model, including
parameterization of AzF and PEG-protein interactions, may enhance the capacity of the model for
quantitative ΔTm prediction.

4.4

Conclusions
Here, we have presented a screening system based on cell-free protein synthesis in order to

rapidly assess the location-dependent impact of PEGylation on protein stability and function with
microliter-scale reactions. Notably, the approach also enables rapid assessment of protein production
yields after uAA incorporation as well as PEGylation efficiency, both of which also vary depending
on the location. Thus, production yields, PEGylation efficiency, and post-PEGylation protein
stability and activity can all be determined and compared relative to other sites in less than two days.
The approach can be used with a wide variety of proteins, where the primary limitation is an inability
to facilitate mammalian post-translational glycosylation [15,21,33,94,97-99]. In addition, we have
developed a coarse-grain simulation tool for rapid in silico screening of protein conjugation sites
and present a linear correlation between simulation and experimental results. Thus the coarse-grain
simulation tools could further expedite the screening process by potentially narrowing the
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experimental screening pool. Finally, we have compared our findings to currently held PEGylation
guidelines and highlight the need for technology such as that presented to rapidly evaluate protein
PEGylation sites, and also provide more data to help develop more accurate and refined PEGylation
guidelines.
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5

PRODUCTION OF THERAPEUTIC PROTEINS IN CFPS FOR PEOZYLATION
OPTIMIZATION

To address concerns about potential generation of anti-PEG antibodies, researchers have
begun to look beyond PEG for biocompatible polymers for pharmacokinetic stabilization of
protein therapeutics. Here we present preliminary work towards enabling PEOzylation
optimization of multiple therapeutics in the cell-free system. The presented work was designed,
led, and conducted by myself, with contributions from my graduate student colleague Emily Long
Zhao.

5.1

Introduction
Acute lymphocytic leukemia (ALL) is the most common childhood cancer in the U.S. Over

the past several decades, survival rates have increased from about 10% to close to 70% or more,
primarily due to the discovery of bacterial asparaginases as effective treatments [153]. These
enzymes deplete blood asparagine levels, selectively targeting leukemia cells which are unable to
synthesize asparagine as healthy cells can. However, the bacterial origin of these asparaginases
make them highly immunogenic, and short half-lives of 1.5 days or less necessitate multiple
administrations weekly. As a result, between 20-40% of patients develop antibodies against the
primary therapeutic, E. coli-derived asparaginase (aspargase), within the first few weeks of
treatment, necessitating treatment with a second asparaginase derived from Erwinia chrysanthemi
bacteria (crisantaspase) [53]. However, because crisantaspase is also highly immunogenic,
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incidence of hypersensitivity or neutralizing antibodies is about 33% [53]. A high rate of relapse
amongst ALL patients exacerbates the immunogenicity problem, as treating these relapsed patients
with the same asparaginase they were treated with previously can cause a “vaccination effect,”
where the administered asparaginase is met with increased hypersensitivity and rapid clearance
[53]. PEGylation of both aspargase and crisantaspase has improved treatment options by reducing
their immunogenicity and dramatically increasing the half-life [53,154]. These PEGylated
asparaginases, however, suffer from two key limitations: (1) PEG-associated toxicities that
develop with frequent administration, such as kidney vacuole formation and anti-PEG antibodies
[155-157], and (2) reduced thermal stability and specific activity [53].
The incidence of anti-PEG antibodies, however, could negatively effect the efficacy of
asparaginase drugs by increaseing their immunogenicty and decreasing their half-life. A promising
alternative to PEGylation is conjugation with another highly water soluble, biocompatible polymer
with better renal clearance: poly(2-ethyl 2-oxazoline) (PEO) (Figure 5-1). Recent work with
PEOzylation (conjugating PEO to a protein) has demonstrated a similar potential for “stealth”
behavior to reduce immunogenicity of conjugated protein therapeutics, and it has been approved
for consumption by the FDA [155,156]. Recent efforts to produce a PEOzylated protein
therapeutic have shown high activity retention, but have been plagued by low conjugation
efficiency and have been limited to native unique sites such as the N-terminus [156]. Therefore,
asparaginase therapies could be improved by enabling higher conjugation efficiency, activity, and
stability through conjugation to a PEO as a PEG alternative.

Figure 5-1: PEG vs PEO structure.
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Careful design of such conjugates allows improvements over the traditional benefits
associated with PEGylation, namely increased half-life and reduced immunogenicity, by
enhancing conjugate stability and activity through selection of an optimal conjugation site.
Unnatural amino acids (uAA) provide the precise control necessary for conjugate optimization due
to unique side chains which can be targeted in orthogonal conjugation reactions [20,24]. However,
inadequate understanding of the effects of polymer conjugation on proteins necessitates testing
many different conjugation sites, which, with traditional in vivo expression, is expensive and
onerous [20]. Chapter 4 discusses the development of an integrated coarse-grain simulation and
cell-free protein synthesis based approach to rapidly determine optimal PEGylation sites [20]. Here,
work is presented towards reengineering this platform for optimization of protein therapeutics.
Production of highly active crisantaspase is optimized. The proposed work would provide the basis
towards the development of an optimized ALL therapeutic and could provide a framework for
development of optimal PEOzylated therapeutics in the future.

5.2

Materials and methods
Materials were purchased from Sigma Aldrich unless otherwise indicated.

5.2.1

Extract preparation
Extracts were made as described previously in sections 2.2.1 and 4.2.1.

5.2.2

Cell-free protein synthesis
CFPS reaction mixtures were based on of the same procedure described in previous

sections, with crisantaspase-specific modifications made during optimization. These modifications
are discussed in section 5.3.
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5.2.3

Protein purification
Ni-NTA spin purification was performed according to the manufacturer’s instructions. For

spin cation exchange chromatography, samples were diluted with buffer (buffers were based on
either 25 mM sodium acetate buffer or 50 mM HEPES buffer, with NaCl added to wash and elution
buffers at concentrations ranging up to 2 M) to a final volume of 400 µL and then applied to Pierce
Strong Cation Exchange Spin Columns (ThermoFisher Scientific) and purified according to the
manufacturer’s instructions.

5.2.4

SDS-PAGE gels and autoradiography
SDS-PAGE gels and corresponding autoradiograms were performed as described in

section 4.2.6.

5.2.5

Activity assays
Activity assays of crisantaspase were performed as described in section 2.2.5.

5.2.6

Stability assays
Stability assays to determine Tm were performed as described in section 4.2.7.1.

5.3

Results and discussion
The first step in developing and evaluated PEOzylated therapeutics in the high-throughput

CFPS system was to re-engineering the CFPS high-throughput screening system for production
and purification of these more complicated proteins. Crisantapase, a tetrameric protein presents
unique challenges for high-throughput optimization, including modified CFPS conditions and
restrictive purification options.
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5.3.1

Crisantaspase production optimization
Crisantaspase (ErA) was initially produced and purified as described in section 2.2.3,

however, it was noted that the purified ErA was only minimally active (~0.1% of reported activity).
We hypothesized that this was a result of steric hindrance due to the C-terminal 6-histidine tag, as
the C-terminus is located at the interface between monomers and is also implicated in enzyme
activity (Figure 5-2). We therefore performed QC mutagenesis to remove the 6-histidine tag and
preceding glycine/serine linker from the C-terminus of the enzyme. Activity analysis of the untagged ErA variant confirmed restoration of activity to levels in good agreement with literature
values (Figure 5-2) [42,161-163]. In connection with the dramatically increased activity, protein
synthesis yields were notably lower. We hypothesized that the decrease in yields represented an
asparagine-limited synthesis reaction for the highly active untagged ErA. Therefore, we assessed
the effect of adding an initial bolus or continuous additions of asparagine in an otherwise standard
CFPS reaction. We found that yields could be nearly doubled by addition of an initial bolus of 15
mM asparaginase (Figure 5-2). Highly active crisantaspase has been produced in a CFPS system,
enabling rapid protein synthesis towards high-throughput PEOzylation optimization.
The next step in the optimization of crisantaspase production is to identify a rapid, reliable
tag-less purification strategy. This would improve the applicability of the screening process by the
production of minimally-modified therapeutics and would be especially advantageous for proteins
which, like crisantaspase, are negatively impacted by C-terminal affinity tags. A more widely
applicable procedure would be ion exchange chromatography. We evaluated the feasibility of
purifying crisantaspase using spin cation exchange columns. Example SDS-PAGE results are
shown in Figure 5-3 with two different buffer systems. An apparent disadvantage of this
purification method is the notably less pure protein fractions. However, using 25 mM sodium
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acetate buffer, pH. 5.5, enables high recovery of ErA with minimal contaminating protein.
Although the pI is expected to change slightly with each different AzF substitution, because the
pH of this buffer is sufficiently lower than the expected pI of ErA, AzF-incorporated ErA should
be amenable to purification under the same conditions [164].

Figure 5-2: Active ErA Production Optimization. (A) Crystal structure of tetrameric ErA showing the
orientation of the C-terminus (red) of one monomer (blue) at the interface between monomers; (B)
Comparison of ErA activity for His-tagged and un-tagged ErA (averages with one standard deviation, n ≥
4); (C) CFPS optimization by asparagine supplementation (averages with one standard deviation, n ≥ 2.
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Figure 5-3: SDS-PAGE Analysis of Spin Cation Exchange-purified ErA Using Different Buffers.

5.3.2

uAA Incorporation and PEOzylation

5.3.2.1 uAA incorporation site selection
In Chapter 4, a CFPS-based high-throughput screening system and a coarse grain
simulation were developed to evaluate current heuristics informing design of optimally PEGylated
proteins. Current heuristics were found to be insufficiently predictive, necessitating a highthroughput screen for optimization of novel conjugates [20]. Therefore, sites for PEOzylation were
selected to span a variety of sites, including locations in α helices, β sheets, and unstructured loops,
moderate to high solvent accessibility, and epitope score. Structural context was evaluated using
Chimera and the published protein structure for crisantaspase (PDB ID 1O7J) [133]. Solvent
accessible surface area was assessed via the web-based program ASA-View, as done previously
for T4 Lysozyme [20]. Because a primary concern for the in vivo stability of crisantaspase is its
high immunogenicity, immunogenicity score was evaluated based on the B cell mapping functions
of the Immune Epitope Database [167-169], which predicts 6-7 epitopes in the crisantaspase
sequence, shown in Figure 2-1A. Amino acid substitutions in predicted epitope sites has been
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demonstrated to reduce the immunogenic potential of some protein therapeutics by reducing their
ability to bind MHC II peptide grooves [170,171]. Therefore, ncAA substitution and subsequent
PEOzylation at sites in these predicted epitopes, such as the predicted immunodominant epitope
between residues 283-293 [170], could simultaneously reduce the binding potential of the peptide
to MHC II and also provide protection against degradation by other immune cells or proteases.
Considering each of these attributes – structural context, solvent accessible surface area, and
immunogenicity, 30 representative sites were selected for uAA screening. We propose to test the
effect of AzF incorporation at each of these sites using the previously presented high-throughput
conjugate screening platform with the CFPS modifications detailed in the previous section. This
work will be continued by Ph.D. candidate Emily Long Zhao.

Figure 5-4: Site Selection for Crisantaspase. (A) Epitope mapping of crisantaspase using IEDB [167-169];
(B) Selected site locations on crisantaspase crystal structure (PDB ID 1O7J). The colored chain represents
one monomer subunit of the tetrameric crisantaspase. Purple regions correspond to immunogenic regions
identified in (A), orange and red regions are indicated in enzyme activity, and green residues indicate sites
selected for PEOzylation screening.

5.3.2.2 PEOzylation scheme
Due to recent reports of possible anti-PEG antibodies, development of alternative polymers
is an active area of research [156]. One such alternative polymer is poly(2-ethyl-2-oxazoline)
(PEOz), which has been reported to have similar stealth properties to PEG with potentially further
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decreased immunogeneicity [155,156]. PEOz was recently conjugated to two sites in G-CSF and
the resulting conjugate maintained high activity [156]. We therefore propose to evaluate the
location-dependent effects of PEOzylation vs PEGylation and enable rapid optimization of
PEOzylated therapeutics via the adapted CFPS-based screen herein described. However, DBCOfunctionalized PEOz for copper-free click chemistry is not commercially available, so we have
identified a reaction scheme to functionalize PEOz with DBCO with a click reaction in order to
minimize reactivity of unreacted linker or PEOz with protein (Figure 5-5). We have procured a
5kDa amine-functionalized PEOz polymer from Sigma Aldrich and a corresponding DBCO-NHS
linker (Click Chemistry Tools). The DBCO-NHS linker will react with the amine group on the
PEOz polymer, however, it is insoluble in water. Therefore, the reaction may be carried out in
organic solvent such as methlylene chloride, which can be easily evaporated following the reaction.
Water can then be added to the dried DBCO functionalization reaction to solubilize the DBCOfunctionalized PEOz and unreacted PEOz, while unreacted DBCO/NHS linker remains insoluble.
The amine-terminated PEOz is not expected to react with any amino acid side chains at
physiological conditions, thereby insuring that PEOzylation remains site-specific.

Figure 5-5: DBCO Functionalization of PEOz.
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5.3.3

Stability evaluation

5.3.3.1 Crisantaspase stability
Stability of wild-type crisantaspase was evaluated using a thermal shift assay as described
in 4.2.7.1. Despite some contaminating proteins in the cation-exchange purified samples, wildtype melting temperatures agreed well with previously reported values, shown in Figure 5-6, where
Tm, dsc represents Tm as determined by differential scanning calorimetry [172] and Tm, act is the
temperature at which the enzyme reportedly loses 50% activity [173] which is understandably
lower than the actual Tm of the protein. Discrepancies between the determined Tm and Tm, dsc may
be due to the high ionic strength of the cation exchange elution buffers. Notably, there was no
significant difference in the Tm between ErA with a C-terminal 6-histidine tag (ErA-6H) and
untagged ErA, supporting the hypothesis that the dramatic decrease in activity of ErA-6H is the
result of steric hindrance from the 6H tag as opposed to significant structural perturbation of the
monomer. We also noted that the stability of the crisantaspase monomer did not differ significantly
between samples purified in sodium acetate buffer or HEPES buffer.

Figure 5-6: Stability of Wild-type Crisantaspase in Cation Exchange Elution Buffers.
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5.3.4

Conclusions and future directions
We have demonstrated production of highly active crisantaspase in a CFPS system, as well

as the highest reported yields of soluble G-CSF. Furthermore, we have adapted the purification
schemes previously used in our high-throughput screening system to accommodate a wider variety
of proteins and have demonstrated precise determination of Tm in these purified fractions. Finally,
the framework has been established for evaluation of the locational impact of site-specific
PEOzylation on two therapeutic proteins with implications in cancer treatment. This research will
be further pursued by Ph.D. student Emily Long Zhao, who will begin the process of AzF
incorporation and PEOzylation and will assess the reliability of linear expression templates (LETs)
as a method for expedited template generation to further streamline PEOzylation evaluation. The
ability to rapidly identify optimal therapeutically relevant polymer-protein conjugates could
potentially expedite optimization of emerging protein therapeutics. Furthermore, the CFPS
expression of these therapeutics is an important step towards on-demand production of protein
therapeutics.
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6

CONCLUSIONS AND FUTURE WORK

In this work, we have made several important advancements towards re-engineering cellfree protein synthesis to improve design and production of future protein therapeutics. We have
improved the platform to be more amenable to distributed, on-demand protein expression by
eliminating endotoxins from the system, enhancing extract storage stability, and demonstrating
lyophilization of a one-pot whole cell-free protein synthesis system in a scalable format. We also
designed a CFPS-based screening platform coupled with a coarse-grain simulation and used this
system to evaluate the locational-dependent effects of site-specific PEGylation. Finally, we have
laid the groundwork for polymer-protein conjugate optimization of therapeutic proteins in the
CFPS by enabling rapid production of high yields of therapeutic proteins, including a multimeric
protein and a disulfide bonded protein.
This work continues through the efforts of multiple students as shown below.
•

Chapter 2: Further work to extend endotoxin-free cell-free expression systems is being
continued by Ph.D. candidate Emily Long Zhao. We are currently extending this system to
a lyophilized, shelf-stable format.

•

Chapter 3: Further work to extend cryoprotection to lyophilized whole cell-free systems
is being continued by Ph.D. candidate Emily Long Zhao.
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•

Chapter 4: Work towards improving PEGylation optimization is being continued by
students in both Dr. Bundy’s and Dr. Knotts’s labs. Ph.D. student Emily Long Zhao will
address the challenge of experimental PEGylation optimization of therapeutic proteins
using therapeutics such as Onconase, crisantaspase, or G-CSF. To further the simulation
work, Ph.D. student Addison Smith and undergraduate student Joshua Wilkerson are
working towards parameterization of uAA such as AzF in the coarse-grain model. Joshua
Wilkerson is also working to continue high-throughput synthesis and stability analysis of
AzF-incorporated T4 lysozyme in order to generate experimental data to validate the
coarse-grain parameters under development.

•

Chapter 5: Continued work towards PEOzylation will be conducted by Emily Long Zhao,
who will address the challenge of high-throughput uAA-incorporation of additional
therapeutic proteins, such as Onconase, GM-CSF, or G-CSF and subsequent conjugation
to PEOz.

Overall, the contributions of this dissertation have furthered the ability to produce nextgeneration therapeutics from a cost-effective on-demand E. coli-based cell-free protein
synthesis system. My hope is this will lead to greater access to improved therapeutics.
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APPENDIX A. SUPPLEMENTARY MATERIALS FOR CHAPTER 2

A.1

Detailed supplementary methods

A.1.1 Extract preparation
Cell extracts were made using either the E. coli BL21 StarTM (DE3) strain (BL21 (DE3)*)
(Invitrogen, Carlsbad, CA) or ClearColi® BL21 DE3 chemically competent cells (Lucigen,
Middleton, WI). Each extract was grown using sterile technique without the addition of antibiotic.
Standard BL21 (DE3)* extract was produced as described previously [35]. Briefly, overnight
cultures of 5 mL of LB were inoculated into 100 mL of 2xYT and incubated at 37°C and 280 rpm
until an OD600 of 2. The 100 mL culture was then inoculated into a 2.5 L shake flask containing
900 mL of 2xYT. T7 RNA Polymerase expression was induced with 1 mM IPTG at an OD600 0.50.7, and cells were harvested in mid-long phase (around OD600 2.5 – 3.5 in this work). Cells were
then harvested, homogenized using an Avestin Emulsiflex-B15 homogenizer, and prepared as
previously described [174]. ClearColi® extracts were prepared similarly, with the following
modifications. First, TB media with 5 g/L or 10 g/L NaCl was used in place of 2xYT to support
higher cell densities of ClearColi® growth. Second, a 100 mL culture was inoculated directly from
a frozen glycerol stock of the ClearColi® BL21 DE3 cells and the culture was allowed to grow
overnight, reaching an OD of 2-3. Cells were induced at a variety of OD600, varying from 0.1 –
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0.7, and harvested at a variety of OD600 ranging from 0.6 – 3.5. Cells were harvested, lysed, and
otherwise prepared according to the same procedure as the standard BL21 (DE3)* cells.

A.1.2 Triton X-114 two-phase extractions
Triton X-114 (Sigma Aldrich) was added to 0.5-1 mL BL21 (DE3)* extracts in a pyrogenfree microcentrifuge tube (VWR) to a final concentration of 1% by volume. Samples were then
incubated at 4°C for 30 minutes with end-over-end spinning, following which they were
transferred to a 37°C water bath for 10 minutes. After these two incubations, the samples were
centrifuged at > 16,000 g for 10 minutes at 25°C. Centrifuged samples presented three phases: a
lower micelle-rich phase, a middle aqueous phase, and an upper oily phase (Figure A-1). The upper
two phases were extracted by pipetting, and the procedure was repeated with the extracted portion
2 additional times. When yields of extracts treated using this method were found to be low, the
method was modified to decrease the processing time. This later method was based off of a
protocol previously reported, with a few modifications [39]. Triton X-114 was added to extract
samples (0.5-1 mL) to a final concentration of 1% by volume. Samples were then vigorously
vortexed and incubated on ice for 5 minutes. Samples were then vortexed again and incubated in
a 37°C water bath for 5 minutes, followed by centrifugation at >16,000 g for 7 minutes at 25°C.
This procedure resulted in the sample layer formations described for the initial protocol, and the
top two phases were likewise removed by pipetting. Yields and endotoxin content were assessed
after 1 or 3 cycles of this phase extraction. Unless otherwise specified, Triton X-114 phase
extraction results in this paper refer to treatment using this shortened protocol.

99

Figure A-1: Triton X-114 2-Phase Extraction with E. coli Cell Extract. Phases formed during Triton X-114
extraction with cell-free extract. The upper two layers are extracted, leaving the endotoxin-rich lower phase.

A.1.3 Polylysine affinity chromatography
PierceTM High Capacity Endotoxin Removal Spin Columns, 0.5 mL were obtained from
ThermoFisher Scientfic. Columns were equilibrated and washed as directed by the manufacturer.
1 mL samples of BL21 (DE3)* extracts were diluted to 2 mL using endotoxin-free LAL reagent
water (Lucigen, Middleton, WI). The 2 mL sample was loaded onto the equilibrated, washed
polylysine spin column and incubated end-over-end at 4°C for 1 hour. Columns were then
centrifuged at 500 g for 1 minute to elute sample, and the eluent was collected in a 15 mL falcon
tube. The collected sample was then loaded into a fresh polylysine spin column and the procedure
was repeated. Samples were tested after 1, 5, and 10 column passes.

A.1.4 Media optimization
Media optimizations were performed in two sets. For the first set, 5 mL LB-Miller media
was inoculated from a frozen glycerol stock of ClearColi® BL21 DE3 Electrocompetent cells and
grown overnight. The 5 mL growths were then each used to inoculate 100 mL of the test media in
a 500 mL shake flask. The shake flask was incubated at 37°C and 280 rpm, with OD600
measurements taken using a Synergy-MX every 30-60 minutes. Media tested included LB-Miller
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with 10-20 g/L total NaCl, 2xYT with 5-20 g/L total NaCl, and TB with 0-15 g/L total NaCl. For
the second set, LB-Miller with 10-20 g/L total NaCl, 2xYT with 5-20 g/L total NaCl, and TB with
0-20 g/L total NaCL were each tested. A 10 mL culture of each medium was inoculated to an
initial OD600 of <0.05 in 50 mL conical centrifuge tubes and incubated at 37 °C and 280 rpm.
OD600 measurements were taken in duplicate every 60-90 minutes for 10 hours.

A.1.5

LAL testing
Multiple dilutions of each sample (1:103 – 1:107) were prepared using endotoxin-free

water (Lonza, Basel, Switzerland) to ensure measurement within the range of the standard curve
of the assay. Samples were loaded into a clear, pyrogen-free 96-well plate and incubated for 10
minutes at 37°C. LAL reagent was then added to the plate using a multichannel pipette, and the
absorbance at 340 nm was monitored using a Synergy-MX microplate reader (BioTek,
Winooski, VT). Each dilution was assayed in duplicate. The time for the absorbance to increase
by 0.03 was recorded and compared to a standard curve prepared with supplied LPS standard in
order to determine the LAL reactivity of the sample in endotoxin equivalent units. This assay is
known to not differentiate between the E. coli lipid IVA and true endotoxin, which results in
endotoxin readings for ClearColi® samples [25,46]. It has been well documented that the activity
of these same samples using cell-based assays reveals the inactivity of this residual lipid IVA in
immune recognition [25,46].
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A.2

Supplementary results and discussion

A.2.1 Pre-expression endotoxin removal via Triton X-114 two-phase extraction
Triton X-114 extraction has been in use for decades and is one of the most common
endotoxin removal strategies [28]. Traditionally, Triton X-114 is added to a protein sample and
incubated at both 4°C and 37°C. Upon centrifugation two phases form due to excluded volume
interactions, with the upper aqueous phase being enriched in protein and the lower micelle-rich
phase being enriched in LPS [27,38]. Extraction of the aqueous layer then allows separation from
the LPS. This technique has been applied with great success to a variety of purified proteins,
with >98% endotoxin removal reported [27,38]. However, multiple repetitions of the procedure
are typically required to sufficiently remove endotoxin, which can further reduce protein recovery
yield and activity [27,38]. Additional purification steps may also be required to remove residual
surfactant [27,41]. However, if Triton X-114 was used to pre-treat CFPS extract, residual Triton
X-114 would likely be removed during protein purification. It may even help reduce endotoxin in
the purified product, as inclusion of Triton X-114 in wash steps of affinity chromatography has
been reported to enhance separation from endotoxin [27].
Triton X-114 two phase extraction was thus used for pre-expression endotoxin removal
from E. coli extract. Two methods were initially compared for Triton X-114 extraction, one with
significantly shorter incubation periods that the other, as described in the Methods. The protocol
employing shorter incubation times removed endotoxin with a similar efficiency as the longer
protocol, yet produced approximately double the yields in protein expression (Figure A-2). The
protocol with shorter 5 min incubation periods was therefore selected for the bulk of this work.
Endotoxin removal and yield retention were assessed after performing the phase extraction one or
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three times, with the results reported in Figure 2-2. While there was significant variability in the
performance of the Triton X-114 treated extracts, the majority of endotoxin extraction and the
majority of the loss of extract activity occurred after the first extraction, with extracts maintaining
~40% of its protein production activity and ~13% of the original endotoxin. After three Triton X114 extractions, the endotoxin content was reduced to ~5% while the extract retained ~30% of its
protein production yield. It should be noted that Triton X-114 two-phase extraction and affinity
based endotoxin removal have been designed for final stage treatment of a protein therapeutic that
has already been significantly purified, whereas untreated cell-free extract contained
approximately 18 million endotoxin units (EU) per milliliter–at least 100 times more than the
initial endotoxin content of untreated samples previously reported [25,27,29,38]. Therefore, while
95% endotoxin removal is consistent with previous reports for Triton X-114 extractions on purified
proteins, due to the high initial endotoxin content of standard CFPS extract, even 95% endotoxin
removal results in significant levels of residual endotoxin (1 MEU/mL). The loss of extract activity
is not unexpected, due to the many small molecules and macromolecules involved in protein
transcription and translation which could be lost during the phase extraction. Further optimization
of Triton X-114 extraction protocols may mitigate some of these losses [41]. However, considering
the loss in activity and the significant concentration of residual endotoxin, additional methods for
endotoxin removal were explored.

103

Figure A-2: Comparison of Triton X-114 Extraction Methods. LAL reactivity and sfGFP yield of untreated
extract and extracts treated with Triton X-114 using the long or short incubation times described in the
methods. Shorter incubation times remove approximately the same amount of endotoxin but preserve
greater activity. Error bars represent standard deviation from n = 4.

A.2.2 Pre-expression endotoxin removal via polylysine affinity chromatography
Another method of endotoxin removal employs affinity adsorption to selectively remove
endotoxin from protein samples. Many successful embodiments of this strategy have exploited
various chemical characteristics of LPS, including its hydrophobicity and negative charge [31].
However, affinity adsorption also presents several challenges. For example, endotoxin adsorption
is reportedly best when performed at a pH near the pI of the desired protein in order to maximize
endotoxin removal and protein recovery; the neutral charge of the protein at this pH is desirable
because positively charged proteins will interact more strongly with endotoxin and negatively
charged proteins will bind to the column along with the endotoxin [31]. This pH guideline is not
always ideal, however, as the target protein may be less stable at this pH. A common endotoxin
adsorbent is polmyxin B, an antibiotic with high affinity for the negatively charged LPS. However,
polymyxin B treatment requires long contact times and can introduce polymyxin B contamination
which must be removed before administration [31]. As an alternative, high capacity polylysine
columns similarly interact with the negatively charged LPS but require only 1 hour contact times.
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Polylysine treatment has also been reported to have improved protein recoveries compared to
polymyxin B treatment [31]. For these reasons, endotoxin removal and cell extract viability after
treatment with polylysine affinity columns were assessed.
Despite the resin’s high reported binding capacity of 2 MEU/mL, extract samples were
diluted 1x with water in order to meet the recommended 4:1 sample to resin ratio without
overwhelming the column. Still, due to the high endotoxin content of untreated extract, multiple
treatments were necessary. Endotoxin content and protein synthesis capability of cell-free extracts
was evaluated after 1, 5, or 10 column passes (Figure 2-2). Although the columns removed a
significant amount of endotoxin, they were less effective than the Triton X-114 treatment. A single
column pass reduced the endotoxin content of the treated extract by ~2 MEU which represented a
decrease of only ~10%, though the extract did retain nearly 60% of its original protein synthesis
activity. Additional column treatments further reduced the endotoxin content, but extract viability
was lost after 5 column passes. The dramatic effect of the polylysine treatment on extract viability
is likely due to the column adsorbing essential CFPS components. For example, at a neutral pH
where the extracts were treated, tRNA, rRNA, and multiple protein components of the E. coli
ribosome are expected to be negatively charged [43]. While the columns effectively removed
endotoxin and further optimization of extract dilution or pH could improve nucleic acid and protein
recovery, the current negative effects on extract protein synthesis activity necessitate further
engineering before such a process is economical for bulk extract preparations.
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APPENDIX B. SUPPLEMENTARY MATERIALS FOR CHAPTER 3

B.1

Estimated percentage water loss during lyophilization

%𝐻𝐻2 𝑂𝑂 𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 =

∆𝑚𝑚𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡

(B-1)

𝑚𝑚𝐻𝐻2𝑂𝑂

(B-2)

𝑚𝑚𝐻𝐻2𝑂𝑂 = 𝜌𝜌𝐻𝐻2𝑂𝑂 × 𝑣𝑣𝑣𝑣𝑣𝑣𝑒𝑒𝑒𝑒𝑒𝑒

(B-3)

𝜌𝜌𝐻𝐻2𝑂𝑂 = 𝜌𝜌𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 − 𝜌𝜌𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝

B.2

Comparison of lyophilization methods

Figure B-1: Comparison of Lyophilization Methods. Samples were dried in either (1) 50 mL falcon tubes
in a LabConco freeze dryer (hollow data points), or (2) 75 mL glass vials on a FlexiDry manifold freeze
dryer (filled data points). In all three formulations tested, the samples dried in the manifold freeze dryer
(FD) performed approximately as well as or slightly better than samples dried in the LabConco freeze-dryer.
Because the manifold freeze drying also allowed for faster drying and, in some cases, visibly more complete
drying, the manifold freeze dryer was used for the bulk of this work.
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Figure B-2: Sample Standard Curve for Protein Concentration Determination using DC Protein Assay.
Bovine serum albumin (BSA) was used as a protein standard, and a new standard was run for each DC
assay.

Figure B-3: DC Protein Assay Results for Rehydrated Lyophilized Extract Using Estimated Rehydration
Ratios. Error represents standard deviation, n = 6 except for Trehalose/DMSO where n = 2.
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Table B-1: Rehydration Ratios for Lyophilized Samples
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APPENDIX C: SUPPLEMENTARY MATERIALS FOR CHAPTER 4

Figure C-1: Evaluating Contributing Factors for Prediction of Conjugate Stability. Relative SASA values
from ASA-View[127] for each incorporation site. For the insertion Ins163, an average SASA of the two
adjacent resides (162 and 163) is used for the evaluation. A: ΔTm vs relative SASA of incorporation site of
unconjugated variants. Note that while there appears to be a weak correlation, it is not predictive of Ins163
or S44, and would not have predicted that S44 would be least destabilized by AzF incorporation; B: ΔTm,conj
vs relative SASA of incorporation site. Again, there appears to be a weak correlation - mostly created by
the low SASA and ΔTm,conj of site L91 – which fails to predict the most stabilized sites, K16 and Ins163.
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Figure C-2: Change in Activity due to PEGylation vs SASA of Incorporation Site. Change in relative
activity, the activity of a lysozyme variant normalized to the activity of the corresponding WT (+ PEG)
reactions, following PEGylation of each mono-AzF-incorporated Lyz shows a general positive trend with
relative SASA of the conjugation site. However, the change in relative activity as a result of PEGylation
was only significant for L91AzF and N53AzF, diminishing the utility of the trend. Nevertheless, the data
indicates that SASA may provide general guidance in relation to which sites may be poor candidates for
conjugation but may not be useful for predicting optimal conjugation sites.

C.1

Coarse-grain simulation

C.1.1 Additional model details
In the Gō-like model, the tertiary structure of the protein is defined by native contacts.
Residues which hydrogen bond in the native structure or have one non-hydrogen atom within 4.5
angstroms of a non-hydrogen atom of another residue form a native contact. The energy of this
interaction, Vij, is defined as according to Equation C-1, where rij is the instantaneous distance
between the Cα of the two residues i and j, εij is the interaction energy between residues i and j,
and σij is the equilibrium distance between the Cα atoms of residues i and j in the crystal structure.
Here, the εij is the same for each residue and is equal to 378. Solvent effects are included implicitly,
as an energy barrier for the water two residues must displace in order to come into close proximity.
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C.1.2 Heat capacity and native contacts results
Coarse-grain replica exchange simulations were run to determine the melting temperature
for lysozyme PEGylated at each of the substitution sites. The change from WT melting temperature
was compared to the experimental results, as reported in the main text. The plots below show the
heat capacity and native contacts traces for WT T4 Lyz and T4 Lyz PEGylated at each of the
substitutions with both PEG sizes. The point of maximum heat capacity is generally taken to be
the protein melting temperature, which agreed well with the point of maximum change in native
contacts. For each PEG size, the positions and magnitudes of the first two peaks appear to be
relatively constant between the five variants, although both peaks are stabilized for all three
variants in the 5kDa PEG conjugate group. Conjugation to site 91 appears to affect primarily the
largest peak, which also corresponds to the greatest change in native contacts and therefore the Tm,
causing it to merge with the second peak. These smaller two peaks are not reflected in the
fluorescence data from the Protein Thermal Shift Assay. However, the general behavior of the
major denaturation peak agrees well with the experimental data – that ΔTm,conj for variants
PEGylated at site 91 is significantly more destabilizing than any other site, K16 is most stabilizing,
and other sites are similar to K16 but slightly less stabilizing (Figure C-3 and Figure C-4).

C.2

Supplemental PEGylation discussion

C.2.1 Possible explanations for absence of PEG size-dependent effects
One possible explanation for the independence from PEG size can be provided by
examining studies which have found conformational stability to be dependent on PEG size. Two
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studies have used smaller PEG oligomers, comparing the stability effects between conjugates of
varying sizes of small PEG oligomers and between the small oligomers and a larger 2kDa PEG
[87,142]. In one such study, the mechanism behind the size-dependent stabilization was found to
be that longer PEG chains decreased the rate of protein unfolding in addition to increasing the rate
of folding, while small PEGs only increased the rate of folding [142]. As the PEG chains used in
this study are significantly larger than the PEG oligomers examined in the aforementioned studies,
it is possible that the 5kDa PEG is sufficiently large to decrease the rate of protein unfolding to a
point that the additional length of the 20kDa PEG has a negligible effect on the unfolding rate.

C.2.2 Difference between immobilization-based and PEGylation-based stabilization
The dramatic destabilization from PEGylation at site L91 is interesting, given that this site
was determined to be the optimal site for lysozyme immobilization [109]. These results indicate
that the effects on protein stability from conjugation to a polymer differ significantly from the
effects due to conjugation to a surface. One possible explanation for this difference is that the
flexible PEG chain does not constrain the protein in the same way that a rigid surface does.
Immobilization was previously shown to stabilize T4 Lyz by eliminating an unfolded intermediate
present in the WT folding mechanism [119]; apparently, the flexible PEG chain does not lead to
the same elimination. To verify this, we performed molecular simulations and found that the
folding of the protein occurs through a 4-state process in both the WT and PEGylated T4 Lyz
variants meaning no intermediate was eliminated as was observed for immobilization [119] (See
Figure C-4). The dominant effect of PEG at L91 may be interference with correct folding rather
than prevention of unfolding. In a study with small PEG oligomers attached to accessible residues,
Lawrence et al. reported that PEGs larger than 2 kDa stabilized protein folding and prevented
protein unfolding [87], an effect similar to that observed with protein immobilization [119]. This
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appears to be the mechanism by which PEGylation at the other sites stabilize T4 Lyz with respect
to the unconjugated mutant, as the folding/unfolding pathway does not appear to be altered by the
PEG (See Figure 4-5 and Figure C-3, and Figure C-4). However, PEGylation at L91 does appear
to alter the shapes and distribution of the heat capacity peaks, suggesting that PEGylation of L91
may impact the folding/unfolding pathway in such a way as to destabilize the protein and
downshift Tm.
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Figure C-3: Heat Capacity and Native Contacts Curves for WT, K16, and S44 from Simulation.
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Figure C-4: Heat Capacity and Native Contacts Curves for N53, L91, and K135 from Simulation. Note that
the heat capacity curves for lysozyme PEGylated at site 91 do not show elimination of any of the three
peaks from the WT curve, but do show the highest temperature peak shifting down to begin merging with
the intermediate temperature peak. This supports the hypothesis that excluded volume interactions due to
PEGylation at this site in some way alters the folding and unfolding kinetics of T4 lysozyme, though no
intermediates seem to be eliminat
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